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PREFACE AND ACKNOWLEDGEMENTS 
I started working in Norway in 2005 at “Glittre”, a pulmonary rehabilitation hospital. 
Working at a rehabilitation clinic, I was mainly working with patients with chronic 
obstructive pulmonary disease (COPD). It became increasingly obvious to me that COPD 
is a common and complex disease, both with regard to its pathophysiology and 
treatment. Therefore, when I became aware of a new PhD project at the Akershus 
University Hospital that would include working with COPD patients, it immediately 
attracted my attention. I was glad to be given the opportunity to assess pulmonary and 
cardiovascular features in this patient group, both with an epidemiological and an 
interventional approach.  
 The initial acronym of the trial was “ROMEO”, but it had to be changed to “RODEO” 
when we realized that ROMEO had been used previously. Seemingly I went from a 
“romantic” approach to a somewhat rougher, but maybe more appropriate description 
of the entire PhD project. According to Wikipedia, rodeo is known as ”a sport that 
involves a committed individual getting on a large bull with the attempt to stay seated 
while the animal tries to buck off the rider. The bull then bucks, rears, kicks, spins, and 
twists in an effort to throw the rider off. This continues for some time until the rider falls 
off the bull or successfully dismounts after completing his ride. “ 
I am very thankful to my two supervisors, Torbjørn Omland and Vidar Søyseth for 
choosing me and their continuous support to complete this work. Vidar with his broad 
expertise in epidemiology and statistics has shown incredible patience with the 
progression of my statistical understanding and knowledge over the years. Torbjørn is 
an international capacity in the field of cardiovascular biomarkers and I am very grateful 
to learn and benefit from his ideas, knowledge and experience.   
Patient recruitment turned out to be more challenging than expected, but thanks to the 
good help and valuable support from Gunn Seim Ekeland and Arne Didrik Høiseth, 
even during my maternity year 2011/2012, we managed to complete the trial. Arne 
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Didrik was also the first author and main contributor to paper I in this thesis when I 
made my first steps and experiences in manuscript review and preparation during 
patient recruitment. I am very grateful for the continuous and profound help and 
support by Gunnar Einvik who was a fundamental contributor with steady advice and 
profound knowledge since the first days of the project. I am also thankful to Ragnhild 
Røysland, Anna Randby and the other PhD students for being wonderful colleagues 
and friends. 
I want to thank Vigdis Bakkelund, who, together with Marit Jørgensen and Annika 
Lorentzen, collected blood samples and assisted with the EndoPat and 
electrocardiographic measurements and who always made things possible with a 
consistent cheerful and positive attitude.  
A great thank you also goes to all the helpful nurses of the pulmonary outpatient clinic at 
the Akershus University Hospital for their help with the spirometric measurements and 
performance of the six-minute walk tests.  
Thanks also to Sverre Lehmann, Eli Nordeide and the staff at the pulmonary 
outpatient clinic at the Haukeland University Hospital who contributed with patients to 
the interventional study.  
For the interventional part of the project, I received valuable help from the Department 
of Good Clinical Practice (GCP), Oslo University Hospital, by Birgitte Lid Adamsen and 
colleagues, monitoring the trial and giving continuous advice during the study period.  
A great thank you also goes of course to all the committed COPD patients and volunteers 
who were willing to contribute to the studies. Thanks to a grant from the Norwegian 
Extra Foundation for Health and Rehabilitation I was able to initiate and perform the 
studies. Thanks also to Astra Zeneca who provided study medication for the trial.  
Through my employment as a research fellow at the University of Oslo I was able to 
finish the trial and I was so lucky to work with and get support from Berit Lund 
Opheim, Vibeke Solberg Bjørklund, Ellen Elisabeth Westgaard and André Øien.  
3 
Being a research fellow at the university I was given the opportunity to teach 
undergraduate medical students in internal medicine and clinical communication and I 
want to thank all the students, patients and my mentor in communication, Pål 
Gulbrandsen, for this giving experience beside my PhD work.  
Finally, I want to thank my beloved family for their support, my parents Antje and Ernst 
Neukamm for giving me their love and profound back-up throughout my life, my 
brothers Christian and Thorsten for always giving me something to lean on and reach 
out for and of course my better part Frode who takes me for who I am and shares all ups 
and downs with me and our wonderful daughters Annika and Eline.  
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ABBREVIATIONS 
ACS  
AECOPD  
AF  
AFL  
AMI  
ATP 
GOLD  
CC  
CoHb 
COPD  
cTnT  
CAT  
CRP  
CV  
CVD  
DSMB 
ECG 
ED  
FAB  
FEV1  
FMD  
FVC  
GCP  
HDL  
HF  
IHD  
IL6  
ITT  
Acute coronary syndrome 
Acute exacerbation of COPD 
Atrial fibrillation 
Atrial flutter 
Acute myocardial infarction  
Adult treatment panel 
Global Initiative for Chronic Obstructive Pulmonary Disease 
Complete case 
Carboxyhemoglobin 
Chronic obstructive pulmonary disease  
Cardiac troponin T 
COPD assessment test 
C-reactive protein 
Coefficient of variation 
Cardiovascular disease 
Data safety and monitoring board 
Electrocardiogram 
Endothelial dysfunction 
Fragment antigen-binding 
Forced expiratory volume in one second 
Flow mediated dilation 
Forced vital capacity 
Good clinical practice 
High-density lipoprotein 
Heart failure 
Ischemic heart disease 
Interleukin 6 
Intention to treat 
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LBBB 
LDL 
LoD 
LoB 
LLN 
LTOT 
LVH 
MMRC 
6MWD 
NIV 
NO 
NSVT 
NT-proBNP 
PAH 
PAT 
PP 
PWV 
RHI 
RCT 
ROS 
RVH 
RVSP 
URL 
WHO 
Left bundle branch block 
Low-density lipoprotein 
Limit of detection 
Limit of blank 
Lower limit of normal  
Long term oxygen therapy 
Left ventricular hypertrophy 
Modified medical research council 
Six minute walking distance 
Non-invasive ventilation 
Nitric oxide 
Non-sustained ventricular tachycardia 
N-terminal B-type natriuretic peptide
Pulmonary arterial hypertension 
Peripheral arterial tonometry 
Per protocol 
Pulse wave velocity 
Reactive hyperemia index 
Randomized controlled trial 
Reactive oxygen species 
Right ventricular hypertrophy 
Right ventricular systolic pressure 
Upper reference limit 
World Health Organization 
  
6 
 
 
LIST OF PAPERS  
 
Paper I:  
Elevated high-sensitivity cardiac troponin T is associated with increased mortality 
after acute exacerbation of chronic obstructive pulmonary disease.     
Arne Didrik Høiseth, Anke Neukamm, Bo Daniel Karlsson, Torbjørn Omland, Pål Haugar 
Brekke, Vidar Søyseth.                                                                                                                                                        
Thorax 2011; 66:775-781.  
 
Paper II:  
High-sensitivity cardiac troponin T levels are increased in stable COPD.          
Anke Neukamm, Arne Didrik Høiseth, Tor-Arne Hagve, Vidar Søyseth, Torbjørn Omland.  
Heart 2013; 99:382-387. 
 
Paper III:  
Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO) 
– a randomized controlled trial.  
Anke Neukamm, Arne Didrik Høiseth, Gunnar Einvik, Sverre Lehmann, Tor-Arne Hagve, 
Vidar Søyseth, Torbjørn Omland.  
 J Intern Med. 2015; 278(1):59-67. 
 
 
 
 
  
7 
 
 
WHAT THIS THESIS IS ABOUT 
 
Chronic obstructive pulmonary disease (COPD) patients represent a major patient group 
worldwide. The incidence of the disease is increasing, resulting in growing morbidity 
and health care expenditures. COPD is a complex disease characterized by inflammatory 
components and frequent comorbidities, including cardiovascular disease, which may 
complicate diagnosis and limit treatment options. In addition, COPD, as well as its 
comorbidities, can be underdiagnosed and may subsequently be undertreated.  
In order to assess the extent and potential implications of subclinical cardiac injury and 
statin effects on the immune, respiratory and cardiovascular systems in COPD, we tested 
the hypotheses that subclinical cardiac injury among patients with an exacerbation of 
COPD is associated with adverse outcome, that COPD is associated with elevation of 
cardiac troponins also in the stable state of the disease, and that statin treatment is 
associated with reduced inflammatory activity, improved pulmonary function and 
enhanced endothelium-dependent vasodilation in stable COPD patients without a clear 
indication for statin therapy. 
We demonstrated that increased circulating troponin T concentrations are associated 
with worse prognosis in exacerbated COPD patients and that troponin T concentrations 
are higher in stable COPD patients than in randomly drawn subjects from the general 
population.  Statin treatment in stable COPD patients did not have an effect on 
pulmonary function, but had anti-inflammatory actions and a beneficial effect on 
vascular function in the subgroup of patients with evidence of increased inflammatory 
activity. 
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INTRODUCTION 
COPD 
History 
Terms describing voluminous lungs, enlarged airspaces (emphysema), as well as cough 
and hypersecretion have been used back to 1679, and there have been different names 
for COPD until the terms chronic bronchitis and emphysema were formally defined at 
the Ciba guest symposium of physicians in 1959 (1). The term COPD was first used in 
1965 and has thereafter taken over as the preferred name for this disease. In 1998 the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) was formed in order to 
increase and spread knowledge and awareness of COPD and to help millions of COPD 
patients to cope with the disease, its comorbidities and complications. 
During the last years the GOLD program has released several revised editions of a 
consensus report: “Global Strategy for the Diagnosis, Management, and Prevention of 
COPD” with the last revised edition published in 2011. Updated reports have been 
released in January 2013, January 2014, and January 2015. The 2015 update adds an 
appendix on Asthma COPD Overlap Syndrome. The GOLD guidelines include a 
classification system of COPD patients by airflow limitation, which is used as an 
important tool to guide therapy. Due to accumulating evidence that COPD is a complex 
disease and that airflow limitation is not closely correlated to many patient-related 
outcomes (2) the new classification from 2011 takes the patient’s exacerbation history 
and symptoms into consideration, as further described below. 
The GOLD document defines COPD as “a common and preventable and treatable disease, 
characterized by persistent airflow limitation that is usually progressive and associated 
with an enhanced chronic pulmonary inflammatory response in the airways and the 
lungs to noxious particles or gases. Exacerbations and comorbidities contribute to the 
overall severity in individual patients” (3).  
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Epidemiology 
 
About 65 million people have moderate to severe COPD worldwide. More than 3 million 
people died of COPD in 2012, which is equal to 6% of all deaths globally that year. More 
than 90% of COPD deaths occur in low- and middle-income countries. The primary 
cause of COPD is tobacco smoke (through tobacco use or second-hand smoke). With 
previous data pointing at greater prevalence and mortality of COPD in men, men and 
women seem now to be equally affected by the disease, possibly reflecting change in 
smoking patterns (www.goldcopd.org). In 2002 COPD was the fifth leading cause of 
death, and during the last years, COPD has become the third leading cause of death 
worldwide (Figure 1).  
 
Figure 1: The 10 leading causes of deaths in the world. Reprinted with permission from 
the WHO media center, http://www.who.int/mediacentre/factsheets/fs310/en/ 
(updated May 2014). 
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Furthermore, one has to be aware of the fact that the disease still is relatively unknown 
in some areas and most likely often underdiagnosed (4-6). COPD is also associated with 
a tremendous economic burden. The total direct costs of respiratory disease are 
estimated to be about 6% of the total health care budget, with COPD accounting for 56% 
(38.6 Billion Euros). In the US the estimated direct costs are 29.5 Billion dollar (7). The 
annual direct COPD-related medical costs in Norway in 2005 were 141 million Euros for 
the population aged ≥40 years, and 284 Euros per COPD patient. The COPD prevalence is 
rising, and COPD exacerbations and hospitalizations account for the greatest proportion 
of the total COPD burden on the health care system (8). 
 
COPD exacerbations 
This thesis discusses papers including COPD patients in the exacerbated as well as in the 
stable state of the disease. A high percentage of COPD patients experience exacerbations. 
The current GOLD guideline definition of a COPD exacerbation is as follows: “An 
exacerbation of COPD is an acute event characterized by a worsening of the patient’s 
respiratory symptoms that is beyond normal day-to-day variation and leads to a change 
in medication” (7). It remains under discussion, however, how COPD exacerbations 
should be defined in clinical practice, and we have reason to believe that exacerbations 
are not always diagnosed, documented and treated in the optimal way.  An exacerbation 
can for example mimic symptoms caused by heart failure, but also symptoms caused by 
worsening anxiety or a pulmonary infection or even a combination of all of these. Having 
frequent exacerbations is now recognized as an important phenotype of COPD patients 
(9). This is important because COPD exacerbations are associated with hyperinflation 
and airway and systemic inflammation and patients with frequent exacerbations have 
been shown to have a worse prognosis (10-12). An early and correct diagnosis of a 
COPD exacerbation, the impact of eventual comorbidities as well as the phenotyping of 
the individual patients would be helpful to provide optimal treatment in COPD patients 
(7).  
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A stable COPD patient is a patient who is not suffering from an exacerbation, defined as 
mentioned above, but there is per today no clear and consistent definition in research as 
well as in clinical practice on the term “stable” in terms of duration or variation criteria 
of a stable period among COPD patients. Therefore, to be able to describe 
pathophysiological features in the stable as well as in the exacerbated state of the 
disease it is important to refine the definitions of these groups and to investigate 
biomarkers and clinical endpoints in both states of the disease. 
 
Etiology  
Smoking is the most important risk factors for the development of COPD, but today it is 
also emphasized that non-smokers can develop the disease. This fact has strengthened 
the interest in and knowledge of other important risk factors for COPD development and 
progression. Other contributing  risk factors include genetic predisposition and 
environmental exposure (13) (particularly smoke, as well as exposure to particles in air 
such as outdoor and indoor air pollution or occupational exposures), age, impaired lung 
growth and development, socioeconomic status, asthma and/or bronchial 
hyperreactivity, as well as chronic bronchitis and infections (3). There are several 
pathophysiological aspects in disease development and progression:  
A) Oxidative stress, mainly from cigarette smoke, but also released from otherwise 
activated inflammatory cells is a major mechanism in the development of COPD which is 
further increased in COPD exacerbations. There is a variety of inflammatory mediators 
that have been shown to be increased in COPD patients.  
B) Imbalance between proteases, enzymes that break down connective tissue and 
antiproteases that protect against this break down is also believed to be an important 
feature of the development of damage and enlargement of the air sacs (alveoli) in the 
lungs, also known as emphysema, a major component of COPD.   
  
12 
 
 
C) COPD patients suffer from persistent air flow limitation and air trapping, gas change 
abnormalities, mucus hyper secretion, recurrent pulmonary infections and 
exacerbations and comorbidities. Exacerbation frequency and comorbidities are 
increasingly recognized as important predictive factors for disease progression and 
prognosis and have been included in the definition, grading and treatment approach of 
the disease. 
 
Diagnosis 
In order to diagnose COPD, spirometric measures are necessary. COPD is today defined 
by persistent airflow limitation, defined in the GOLD guideline as a forced expiratory 
volume in one second (FEV1) <80% of the predicted, and FEV1<70% of the forced vital 
capacity (FVC), even after administration of bronchodilatory agents (FEV1/FVC).  
Other studies use values below the lower limit of normal (LLN) which is defined as the 
FEV1/FVC ratio below the 5th percentile. According to prevalence studies FEV1/FVC 
<70% alone might overdiagnose and FEV1/FVC<LLN might underdiagnose COPD (14). 
In addition to spirometric measures one has to evaluate symptoms as dyspnea, chronic 
cough or sputum production, number of exacerbations and comorbidities in the patients. 
Standardized and validated questionnaires are used to evaluate subjective symptoms. 
These are the modified Medical Research Council questionnaire (mMRC) for the 
evaluation of dyspnea and the more recent COPD Assessment Test (CAT, (15, 16)) 
addressing primarily the evaluation of symptoms and functionality of the patient.  
Following the recent GOLD guidelines (http://www.goldcopd.org) each patient can be 
categorized into one of four groups according to their symptoms, exacerbation history 
and spirometry as illustrated in Figure 2 and receive corresponding recommended 
treatment. 
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Figure 2: Combined COPD assessment (GOLD guidelines, updated 2014).  From the 
Global Strategy for Diagnosis, Management and Prevention of COPD 2015, © Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), all rights reserved. Available 
from http://www.goldcopd.org. 
 
Treatment 
There are several therapeutic options for COPD patients. For patients who still smoke, 
smoking cessation is critical to influence the natural history of the disease. Pulmonary 
rehabilitation plays an important part in improving the disease state and quality of life 
of COPD patients. Vaccinations are recommended to prevent pneumococcal and 
influenza infections. Pharmacological therapy for stable COPD includes bronchodilators, 
beta2-agonists, anticholinergics, methylxanthines, corticosteroids and 
phophodiesterase-4 inhibitors. The treatment is supported by randomized controlled 
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trial data suggesting no harmful effect of classic bronchodilators and potentially benefits 
of an anti-inflammatory approach in COPD treatment (17-19).  Patients with alpha-1 
antitrypsin deficiency are treated with alpha 1-antitrypsin augmentation therapy. 
Overall, it is important that therapies are based on a risk/benefit assessment in the 
individual patient with the consideration of all comorbidities, symptoms and GOLD risk 
factors (lung function and exacerbation history). Non-invasive ventilation (NIV) is also 
increasingly used with stable severe COPD but there is insufficient evidence to formulate 
recommendations. Smoking cessation for those who are still smoking and long-term use 
of supplemental oxygen (LTOT) in those with severe resting hypoxemia are the only 
therapies that have clearly been shown to improve survival in patients with COPD. 
Almagro and colleagues suggested that management of co-morbidities contributes as 
much to improved survival as increased use of long-acting β2 agonists and 
anticholinergics at hospital discharge (20). Comorbidities that occur frequently in COPD 
patients include cardiovascular disease, skeletal muscle disease, metabolic syndrome, 
osteoporosis, depression and lung cancer. Today, we know that comorbidities contribute 
significantly to disease severity and outcome. Comorbidities can occur in patients with 
mild, moderate or severe airflow limitation (2), influence mortality and hospitalizations 
independently (21) and deserve therefore increased attention and specific treatment. 
Comorbidities were therefore included in the GOLD definition of COPD in 2006 and the 
importance stated even more clearly in the revised statement from 2011. Today, we 
know that it is important to routinely look for comorbidities in COPD patients in order to 
treat them in time and appropriately.  
 
COPD and inflammation 
 
COPD is considered to be an inflammatory disease, and the major risk factor of COPD, 
tobacco smoking, is a potent stimulus for inflammation and leads to increased oxidative 
stress. Reactive oxygen species (ROS) and cytokines from the pulmonary system 
probably leak over to the systemic circulation and release pro-inflammatory cytokines 
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and acute phase proteins, which again lead to systemic inflammation and change in 
vasomotor and endothelial function and increased concentration of pro-coagulant 
factors. Still, systemic inflammation can persist after smoking cessation (22) and 
increases during exacerbation of the disease. The pathophysiological mechanisms of 
systemic inflammation in COPD are still not completely understood. The factors causing 
systemic inflammation in COPD patients are likely to be multifactorial. COPD often 
coexists with one or more systemic comorbid conditions, such as osteoporosis, cachexia, 
muscle weakness or cardiovascular disease. Complicating the picture, these conditions 
are often associated with systemic inflammation either as a consequence of or as a 
stimulus for the inflammatory process itself. Another stimulus for systemic 
inflammation can also be recurrent exacerbations with increased bacterial colonization 
and viral infections (9). A relation between COPD and markers of low-grade systemic 
inflammation has been demonstrated in numerous studies (23, 24). Inflammatory 
biomarkers such as C-reactive protein (CRP) and Interleukin 6 (IL6) have been shown to 
be increased among COPD patients (25) and are associated with poor clinical outcomes 
and improve clinical prediction of mortality in patients with COPD (26, 27). Various 
markers of systemic inflammation were investigated in the Framingham Heart Study 
(28) and showed a significant relation between increase in IL6 and CRP and decrease in 
FEV1 after adjusting for age, sex, BMI and smoking. Another study including stable COPD 
patients showed that subjects with elevated CRP levels had more severe airflow 
obstruction than subjects with normal CRP levels (29). In the Copenhagen City Heart 
Study (30) hospital admissions and mortality were highest among COPD patients with a 
CRP level >3 mg/l at inclusion. Additional analysis from the Copenhagen General 
Population Study showed that simultaneously elevated levels of CRP, fibrinogen, and 
leukocyte counts were associated with a two- to four-fold risk of major comorbidities in 
COPD (31). In the Lung Health Study (32), the association between the risk of both fatal 
and nonfatal cardiovascular events was increased two- to three-fold in patients with the 
highest quintile of CRP compared with those with the lowest quintile. However, another 
observational study found no association between CRP levels and mortality after a 
follow-up of three years of patients with moderate-to-severe COPD (33).  
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COPD and cardiovascular disease  
Cardiovascular disease is a major comorbidity in COPD (34-37). General population 
studies and studies in patients with COPD indicate that COPD is an important risk factor 
for ischemic heart disease and sudden cardiac death. There is evidence of an association 
between COPD and cardiovascular disease, and although COPD and cardiovascular 
disease clearly share common risk factors such as smoking, COPD has been described as 
an independent risk factor for the development of cardiovascular disease (21, 38).  
The Atherosclerosis Risk in Communities (ARIC) study, a longitudinal, population-based 
study with 15759 participants, 3434 COPD cases and a mean follow-up time of 9 years 
reported up to 27% cardiovascular deaths among patients with mild and moderate 
COPD (39). The TORCH study, a randomized, double-blind, placebo controlled trial 
including 6184 COPD patients and a three year follow-up time described that 27% of all 
deaths in COPD patients were related to cardiovascular causes (40). In a postmortem 
analysis, the leading cause of death was cardiac failure, accounting for 37% of all deaths 
among hospitalized COPD patients (41). In a large cohort of 384 888 patients with COPD 
admitted to a Veterans Administration hospital or clinic, the prevalence of coronary 
artery disease was 33.6%, significantly higher than the 27.1% prevalence seen in a 
matched cohort without COPD (42).  A number of population studies have shown that 
airflow limitation as measured by FEV1 or FEV1/FVC ratio is a predictor of 
cardiovascular risk and describe FEV1 as an independent predictor of cardiovascular 
mortality in COPD (43). The Lung Health Study (44) reported that the 5-year mortality 
in 5 887 patients aged 35 to 46 years with COPD and mild to moderate airways 
obstruction was 2.5%, of whom 25% died of a cardiovascular event. For every 10% 
decrease in FEV1 there was an increase of about 28% in fatal coronary events and 20% 
in nonfatal coronary events among subjects with mild to moderate COPD. COPD also 
frequently co-exists with heart failure and the two diseases share common 
pathophysiological features, risk factors as well as similar symptoms. They also have the 
potential to camouflage the existence of each other in the individual patient (45).  
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Chronic heart failure has been found to be prevalent in more than 20% of COPD patients 
(46), and right heart failure is relatively frequent and related to the severity of hypoxia 
(47). 
 
Figure 3: Inflammation and comorbidity in COPD, L.M. Fabbri et al. ERJ 2008: 
Reproduced with permission of the European Respiratory Society © Eur Respir J    
 
It is a matter of debate whether COPD itself might act as an independent risk factor for 
the progression of the atherosclerotic process and development of cardiovascular 
disease. It has also been shown that the risk for cardiovascular events is increased 
following exacerbations of COPD (48). Inflammation has been proposed as a link 
between COPD and CVD, with a possible spillover of inflammatory mediators from the 
lungs to the peripheral blood (49) (Figure 3). Inflammatory mediators (CRP, IL6 and 
others) have been found to be increased in sputum and bronchioalveolar lavage samples 
as well as in circulating blood (23).  In addition, arterial stiffness is increased in COPD 
patients, more in more severe COPD, which may be an effect of vascular inflammation 
(50, 51).  Shared risk factors as smoking might explain the relation between COPD and 
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cardiovascular disease, but environmental and genetic risk factors might also influence 
the inflammatory state and the potential for the development of cardiovascular disease 
among COPD patients.  However, the mechanisms responsible for the increased risk of 
cardiovascular disease in patients with COPD are still not fully understood. 
 
CARDIOVASCULAR DISEASE 
Epidemiology 
Cardiovascular disease (CVD) is defined as a group of disorders of the heart and blood 
vessels and includes coronary heart disease (CHD), cerebrovascular disease, peripheral 
arterial disease, rheumatic heart disease, congenital heart disease and venous 
thromboembolism (WHO, Department of Cardiovascular Diseases. Fact sheet N°317, 
updated January 2015). CVD is a leading cause of morbidity and mortality throughout 
the world. According to the World Health Organization, about 17 million deaths per year 
can be attributed to CVD. This number is expected to rise with the shift in demographics 
to an aging population in the Western world (52) and an increase in traditional risk 
factors (smoking, hypertension, diabetes, dyslipidemia) in the developing world. By 
2030 more than 23 million people are suspected to die annually from CVD.  
 
Etiology  
This thesis focuses on atherosclerosis as the major antecedent event in the development 
of CVD and the acute coronary syndrome. Atherosclerosis has during the past 2 decades 
been increasingly recognized to be an inflammatory disorder and not simply a 
cholesterol storage disease (53). Atherosclerotic lesions, also known as atheromas, are 
local thickenings of the intima consisting of inflammatory, endothelial and smooth 
muscle cells, lipids and cellular debris. Prior to atheroma development so-called fatty 
streaks, i.e. areas with accumulated macrophages and T-cells beneath the vascular 
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endothelium can be detected.  An acute coronary event and subsequent myocardial 
infarction may occur when the atheromatous process prevents blood flow through the 
coronary artery, a process most commonly caused by the rupture or erosion of an 
atherosclerotic plaque resulting in thrombotic occlusion of the vessel (54). 
 
Diagnosis 
 
An important diagnostic tool in CVD is the clinical history of the patient and physical 
examination for signs of heart disease, such as for example shortness of breath, cyanosis, 
heart murmurs or edema. In addition, electrocardiograms at rest and during exercise 
may provide valuable information concerning cardiac function. Imaging techniques such 
as echocardiography, chest radiographs, computed tomography, coronary angiography 
and cardiac catheterization or cardiac magnetic resonance imaging are used when 
deemed necessary for a correct diagnosis of CVD in the individual patient. In addition, 
biomarkers such as cardiac troponins and B-natriuretic peptides play an important role 
as diagnostic tools.  
 
Prevention and treatment                                                                                                                                  
One has to differentiate between preventive treatment and treatment of established 
CVD. Primary prevention addresses individuals with risk factors who have not yet 
developed clinically manifest CVD. Secondary prevention addresses individuals with 
established CHD, cerebrovascular disease or peripheral vascular disease. (World Health 
Organization, Department of Cardiovascular Diseases. Fact sheet N°317, updated 
January 2015, (55, 56)). It is useful to estimate the total cardiovascular risk in the 
primary prevention group. The Framingham Heart study helped to identify major CVD 
risk factors - high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and 
physical inactivity (57) and the concept of CVD risk classification has led to the 
development of effective treatment and prevention strategies in clinical practice. Such 
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strategies in primary prevention include lifestyle changes such as smoking cessation, 
dietary changes, increased physical activity, and weight control. Depending on risk 
scores and clinical measurements, treatment strategies may include anti-hypertensive 
drugs, lipid-lowering drugs such as statins or even antidiabetic or antiplatelet treatment. 
The major guidelines influencing clinical practice are the Adult Treatment panel (ATP) 
III guidelines developed by the National Cholesterol Education Program (NCEP) expert 
panel (58) , followed by the American College of Cardiology/American Heart Association 
(ACC/AHA) task force (59), and the European Society of Cardiology (ESC) (60). 
Individuals with proven CHD are at risk of developing recurrent cardiovascular events 
and there are currently no risk prediction tools to guide therapy. The treatment aim of 
secondary prevention in this group is to reduce symptoms and to slow the 
atherosclerotic process in order to prevent future cardiovascular events with the same 
treatment options as mentioned above. In addition, angiotensin receptor antagonists 
(ARB’s), angiotensin converting enzyme inhibitors (ACE inhibitors) and beta-blockers 
are recommended in selected patients, depending on previous medical history.  
 
Atherosclerosis and endothelial function  
The endothelium plays a central role in the regulation of the vessel tone and defense 
against atherosclerosis. Endothelium-derived nitric oxide (NO) has been identified as a 
potent vasodilator and an important antiatherogenic agent. Additional actions of NO, 
include inhibition of platelet aggregation, monocyte adhesion to endothelial cells, and 
abnormal smooth muscle cell proliferation (61). Endothelial dysfunction (ED) occurs in 
the presence of vasoconstrictive, growth-promoting, procoagulant and proinflammatory 
factors (62). ED is often present long before CVD is clinically apparent (63) and the 
assessment of endothelial function is now widely recognized as an important index in 
the early assessment of CVD risk (64) (Figure 4).  
There are several different invasive and noninvasive methods to assess endothelial 
function. Invasive methods include intracoronary or -brachial infusion of vasoactive 
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agents such as acetylcholine. Non-invasive methods include the measurement of 
endothelial cell adhesion molecule expression and release of key hemostatic regulatory 
molecules (65) as well as the measurement of endothelium-dependent vasodilatation by 
either ultrasound, gauge-strain plethysmography (66) or peripheral arterial tonometry. 
Flow-mediated vasodilation using ultrasound (FMD) and peripheral arterial tonometry 
(PAT) are further described below.  
 
Figure 4: Atherosclerosis timeline demonstrating endothelial function as an early      
sign of atherosclerosis, Reprinted with permission from Elsevier from Pepine CJ, AM J 
Cardiol, 1998 (67), reproduced from Stary et al. Circulation, 1995 (68). 
It is important to be aware of the fact that reports on “endothelial function” and 
“dysfunction” that are based on different measurements of endothelium-dependent 
dilatation provide only insights concerning one aspect of endothelial physiology. In this 
work endothelial function was assessed using PAT, a non-invasive method to quantify 
digital endothelium-dependent vasodilation. 
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Measurement of endothelium-dependent vasodilation using an ultrasound technique 
was first described in 1992 by Celermajer and colleagues (69). The test used involved 
noninvasive measurement of the diameter of the brachial artery by ultrasound before 
and after shear stress, a known stimulus for NO production, was induced by reactive 
hyperemia (70). This method is commonly known as the brachial artery ultrasound 
(BAUS) flow-mediated dilation (FMD) method (71). Another method of measuring 
endothelial vasomotor function after reactive hyperemia is by PAT (72) and involves 
quantifying arterial pulsatile volume at rest as well as during a condition of increased 
shear stress that results in the release of NO (and other mediators). It is performed with 
the use of a finger plethysmograph with the EndoPat™ method (Itamar Medical, 
Caesarea, Israel). Although the distal fingertip is not an intuitively obvious place to look 
for endothelial dysfunction as a marker of atherosclerosis risk, the peripheral vascular 
beds located at the distal part of the limbs are major sites of sympathetic alpha-
adrenergic vasoconstrictor activity and therefore play an important role in circulatory 
regulation (73). It appears that endogenous NO-mediated vasoregulation is particularly 
prominent in the arteriovenuous anastomoses in the human fingertips (74) and it has 
been shown that approximately 60% of the PAT response is mediated by NO release 
(75). Two great advantages of the EndoPat™ method are that the method, in contrast to 
the FMD method, is operator independent, and measurements are normalized to the 
contralateral arm, adjusting for systemic effects that affect blood flow. 
 
Endothelial function in COPD 
Studies on endothelial function in COPD are limited. Barr and colleagues (76) found in 
2007 that endothelial dysfunction measured by FMD was independently associated with 
FEV1 and the percentage of emphysema (measured with CT) in former smokers. These 
associations were linear across a spectrum of disease from normal pulmonary function 
and anatomy to moderate to severe COPD and emphysema. Eickhoff and colleagues (77) 
described a significant lower FMD in patients with moderate to severe COPD compared 
with smoking control subjects and a strong correlation of FMD and markers of systemic 
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inflammation and severity of airflow obstruction measured by spirometry independent 
of smoking history.  It has also been shown that endothelial function measured by FMD 
is impaired during COPD exacerbations and improves after their resolution (78). 
Assessment of endothelial function with digital pulse wave tonometry is a relatively new 
validated method (64, 79) and only sparse data have been published on endothelial 
function in COPD patients with this method. Minet and colleagues (80) reported that 
endothelial dysfunction determined by EndoPat ™ occurred in half of the studied COPD 
patients and was amplified during COPD exacerbation. They also found that functional 
capacity assessed by the six-minute walking distance (6MWD) was a main predictor of 
endothelial dysfunction in COPD patients. 
 
CVD – biomarkers, risk markers and risk factors  
A biomarker has been defined as “ a biological characteristic that is objectively measured 
and evaluated as an indicator of a normal or pathogenic biological process or a 
pharmacological response to a therapeutic intervention”(81). If this characteristic is 
quantitatively associated with a disease or other outcome, but does not necessarily 
contribute to disease progression it can be defined as a risk marker. A risk factor is any 
attribute, characteristic or exposure that increases the likelihood of developing a disease 
or an injury. A risk marker can be considered a risk factor if intervention to modulate 
this factor results in parallel modulation of risk, provided that the analysis 
demonstrating this risk modulation accounts for possible confounding factors. 
Moderators of risk factors provide information on who is susceptible to an exposure and 
improve our understanding of disease etiology and early diagnosis. This is important in 
identifying subpopulations with a possible beneficial treatment effect. Identification of 
mediators of risk factors, factors explaining how and why other risk factors affect the 
outcome, can lead to the design of interventions for the prevention or early detection of 
diseases. To be considered a risk mediator, the factor must show a strong correlation 
with an increased likelihood of a disease, occur after another relevant risk factor and 
must also contribute directly to the development of disease. A clinical endpoint is a 
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characteristic or variable that reflects how a patient feels, functions or survives. A 
surrogate endpoint is a biomarker intended to substitute for a clinical endpoint and is 
expected to predict clinical benefit or harm based on epidemiologic, therapeutic, 
pathophysiologic or other scientific evidence (81).  
Smoking, obesity, arterial hypertension, diabetes mellitus, blood lipid composition, age, 
ethnicity and genetic predisposition are all examples of established risk factors for 
cardiovascular disease. This thesis focuses on inflammatory markers (CRP and IL6), 
troponin T and endothelial function measured by PAT as the main outcome 
measurements. Inflammation has been shown to play a central role in the development 
of atherosclerosis (82) and inflammatory biomarkers such as C-reactive protein (CRP) 
have been shown to be associated with the development of CVD (83). However it has 
been under debate if CRP should be declared a risk factor or a risk mediator for CVD (84, 
85), but there is so far no clear evidence for CRP as a pathogenetic factor in 
cardiovascular disease (84, 86). Cardiac troponins are established biomarkers for 
myocardial injury and risk markers in acute coronary syndromes (ACS) as well as in 
populations without ACS as further described below. Endothelial function including non-
invasive peripheral arterial tonometry (EndoPATTM) is an established biomarker in 
clinical research both as a surrogate marker for subclinical atherosclerosis and as a risk 
marker of future cardiovascular events (87). EndoPATTM has been shown to predict 
cardiovascular events in low-risk subjects with unexplained chest pain (88) and in 
subjects with heart failure with preserved ejection fraction (89) as well as in high-risk 
populations (90).   
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CARDIAC TROPONINS 
History 
Today, cardiac troponin I (cTnI) and cardiac troponin T (cTnT) have received 
international endorsement as the standard biomarkers for detection of myocardial 
injury, for risk stratification in patients with a suspected acute coronary syndrome, and 
for the diagnosis of myocardial infarction (91, 92). After assays were developed in the 
1980’s, the diagnostic use of troponin T testing as a cardiac injury marker was 
incorporated in the definition of acute myocardial infarction (AMI) from the First Global 
MI Task force in the year 2000 (93).  Later, the definition was refined in the Universal 
Definition of Myocardial Infarction Consensus Document in 2007 (91) and 2012 (94) 
emphasizing different conditions leading to a MI and the addition of cardiac troponins 
with a typical rise and gradual fall as the preferred diagnostic biomarker of 
cardiomyocyte necrosis. The Third Universal Definition of Myocardial Infarction from 
2012 additionally emphasizes the differentiation between myocardial injury and 
infarction and discusses the challenges in interpretation of elevated troponin values 
measured by the new high sensitivity assays. 
Over the last decades, several troponin assays have been developed with successive 
generations with increasing ability to detect low levels of troponin. In contrast to cTnI, 
there is only one manufacturer for the cTnT assay, allowing for the standardization 
across institutions. The first-generation assay for cTnT used bovine cTnT as the 
reference material with a non-specific binding to human skeletal muscle troponin. The 
second-generation assay for cardiac troponin T (cTnT) was completely specific for the 
cardiac isoform of TnT, utilizing two cardiac specific monoclonal antibodies, although 
still with a possible certain amount of cross-reactivity of skeletal muscle (95). With the 
third generation assay the use of recombinant human cTnT for standardization refined 
the specificity of the assay. The fourth-generation cTnT assay uses fragment antigen-
binding (FAB) of two cTnT-specific mouse monoclonal antibodies in a sandwich format. 
The antibodies recognize epitopes located in the central part of the cTnT molecule 
without any cross-reactivity.   
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In 2012 experts agreed on a consensus on nomenclature for high-sensitivity assays that 
defined that they should have a coefficient of variance (CV) of <10% at the 99th 
percentile upper reference limit (URL) value in the population of interest. To be 
classified as high-sensitivity assays, concentrations below the 99th percentile should be 
detectable above the assay’s limit of detection for >50% (ideally more than 95%) of 
healthy individuals in the population of interest (96, 97). The new methods have 
incrementally reduced the diagnostic cut-offs for the rule-out of MI from 0.5 μg/L in the 
first generation assays to the levels of 0.05–0.1 μg/L in the third generation and the level 
of 0.03 μg/L in the fourth generation assay. The fourth-generation cTnT assay has a limit 
of detection (LoD) of 0.01 ng/mL, a 99th percentile cut-off point of 0.01ng/mL, and a 
10% coefficient of variation (CV) at 0.03 ng/mL. For the diagnosis of AMI, the fourth-
generation cTnT assay is still considered the standard assay in the United States, 
whereas the new high-sensitivity (hs) cTnT assay is used in Europe and Asia.  
 
 The troponin complex 
The troponin complex is found in striated muscle tissue and consists of three different 
polypeptides: troponin C, troponin T, and troponin I. Troponins are predominantly 
sarcomere-bound, but a small (<10% of total) cytoplasmic pool of troponins is present 
as illustrated in Figure 5. Whereas troponin C found in cardiomyocytes is identical to 
troponin C found in striated skeletal muscle, troponin I and T in the heart are genetically 
and immunologically distinct from the troponin I and T isoforms of the skeletal muscle. 
Accordingly, the isoforms of troponins I and T in the heart (cTnI, cTnT) are considered 
to be cardiac specific. Thus, the presence of cTnI and cTnT in peripheral blood indicates 
leakage from cardiomyocytes (98). When myocyte damage occurs, the cytoplasmic pool 
is released first, followed by a more prolonged release from myofilament bound 
troponin. Minimal myocardial necrosis can cause troponin elevations at a much lower 
level than after extensive myocardial necrosis and high-sensitive assays are essential to 
detect those concentrations (99).   
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Figure 5: Release of cardiac troponins in acute myocardial infarction. With courtesy 
from Omland T, Journal of Internal Medicine, 2010 (100), reproduced with permission 
from Antman EM, N Engl J Med, 2002 (99). Copyright Massachusetts Medical Society. 
 
High sensitivity troponin T assay  
The new high-sensitive cTnT (hs-cTnT) assay is a modification of the fourth-generation 
cTnT assay. The detection antibody was genetically re-engineered to further reduce the 
susceptibility to interference by heterophilic antibodies. The variable region of the 
detection antibody is identical to that of the fourth-generation assay. The analytical 
sensitivity was improved by increasing the sample volume from 15 μL to 50 μL, 
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increasing the ruthenium concentration of the detection antibody, and lowering the 
background signal via buffer optimization. The development of high-sensitivity troponin 
T (hsTnT) assays (Roche Elecsys) can detect levels as low as 0.005 μg/L (5 ng/L) and 
has an upper limit of normal (99th centile) of 14 ng/L. Compared to conventional assays, 
which have a level of detection of 10 ng/L, and detectable levels in < 1% of subjects in 
the general population (101) the hs-cTnT assay measures concentrations that are 
tenfold lower than with the conventional assays, and 25-67% of the general population 
have been shown to have detectable levels (102, 103). 97.7% of patients with stable 
coronary artery disease (CAD) have been shown to have detectable levels of cTnT with 
this type of assay (104). hs-cTnT levels above the detection limit are associated with 
cardiac structure and impaired function and predictive of heart failure, cardiovascular 
death and all-cause mortality (103). But increased sensitivity leads also to reduced 
specificity, which means that low troponin concentrations are now also detectable 
among patients without symptomatic ischemic heart disease. It remains therefore a 
challenge to define the clinical importance of detectable cardiac troponin in patients 
without symptomatic heart disease. 
 
Interpretation 
Detection of cTnT or cTnI above the 99th percentile of a reference population is today a 
prerequisite for the diagnosis of AMI (94). As mentioned above, the highly sensitive tests 
improve AMI diagnostics but also challenge the interpretation and use of troponin 
values in clinical settings due to reduced specificity. We know today that elevations of 
cardiac troponins above the 99th percentile URL are not only found in patients with 
acute myocardial infarction and seem to be associated with structural changes of the 
myocardium (ventricular hypertrophy, remodeling or dysfunction), arrhythmia as well 
as with other conditions such as advanced age and male gender, impaired renal function, 
sepsis and severe pulmonary hypertension or embolism, as illustrated in Figure 6.  
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Figure 6: Cardiac and non-cardiac causes of troponin elevation. Reprinted from Mahajan 
et al. (105), reproduced from Jaffe AS (106) with permission from Elsevier. 
 
Elevated troponin levels are commonly found among patients with structural heart 
disease, including stable coronary artery disease (107, 108) and heart failure (109), and 
in up to 2% of the general population (102, 103, 110). This is important because 
troponin elevations have been shown to be associated with adverse clinical outcomes in 
patients with acute myocardial infarction, as well as stable coronary artery disease 
(107), chronic heart failure (109), acute pulmonary embolism or chronic pulmonary 
arterial hypertension (111, 112). Some studies also suggest a possible cross reactivity of 
cTnT in skeletal muscular disease (113), but this needs to be confirmed in further 
investigations. It remains unclear how and to what extend cardiac troponin is released 
in conditions other than myocardial necrosis. The suggested pathophysiological 
mechanisms underlying troponin elevations are apoptosis, increased myocyte turnover, 
cellular release of proteolytic troponin degradation products, increased cellular wall 
permeability or formation and release of membranous blebs. Extreme exertion such as 
marathon running has also been associated with troponin release (114, 115). 
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Interestingly, the troponin half-life appears to be shorter than observed after AMI, 
suggesting a cytoplasmic rather than a structural origin of troponin in this context. 
(116). Whether cardiac troponins are released after reversible ischemia induced by 
stress-testing or rapid pacing is controversial (117, 118). Sabatine and colleagues 
detected changes in circulating cTnI that were associated with the degree of myocardial 
ischemia induced by transient stress-testing (119). Turer and colleagues measured 
troponin by the high-sensitivity assay after coronary pacing and their findings suggested 
that the heart may release troponin T also under conditions of moderate cardiac stress 
and in the absence of underlying CAD or apparent ischemia (120). 
 
Troponin and COPD 
Previous studies evaluating the association between COPD and cardiac troponin in 
general have mainly focused on patients with COPD exacerbations or have used COPD as 
a covariate for comorbidity. Retrospective data have shown elevations of cardiac 
troponin during COPD exacerbations (121) and that troponin elevation is associated 
with decreased survival in this patient group (122-125).  One prospective study from 
2003 describes a predictive value of Troponin I for in-hospital deaths among patients 
hospitalized for severe AECOPD (126). A summary of papers published previous to our 
first article is presented in Table 1. With mainly retrospective data present at that time, 
we wanted to provide prospective data on the association between cardiac troponin and 
survival in COPD patients hospitalized for an exacerbation. In addition there were no 
data on troponin levels in patients with COPD in the stable state of the disease and in 
paper II we wanted to expand the knowledge about myocardial affection measured by 
hs-cTnT in this particular group compared to the general population.  
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Table 1:  Publications until the year 2009 addressing AECOPD and Troponin.  
Year Author Population troponin cut-off Troponin 
positive 
Mortality 
2003 Baillard 
(126) 
 
ICU patients, n=71 
Severe AECOPD 
Prospective 
cTnI >0.5μg/L 18% OR 6.5, 24 hour in 
hospital mortality 
2004 Harvey 
(121) 
AECOPD , n=235 
Retrospective 
cTnI >0.4μg/L 
cTnT>0.03 μg/L 
25% Prevalence study 
2008 Brekke 
(122) 
AECOPD, n=396 
Retrospective 
cTnT ≥0.04μg/L  25% HR 1.6, 1.9 years 
mean follow-up  
2009 Fruchter 
(123) 
AECOPD, n=182 
Retrospective 
cTnI >0.03 μg/L 46% HR 1.3, 4.2 years 
mean follow-up 
2009 Martins 
(124) 
AECOPD, n=173 
Retrospective 
cTnI > 0.03 μg/L  70% MRR 1.7,  1.5 years 
mean follow-up 
AECOPD, acute exacerbation of COPD; cTnI, cardiac Troponin I; cTnT, cardiac Troponin T; HR, 
hazard ratio; ICU, intensive care unit; MRR, mortality rate ratio; OR, odds ratio. 
 
STATINS 
History  
In the 1970s the Japanese microbiologist Akira Endo discovered a fermentation product 
(compactin) of Penicillium citrinum that had a strong inhibitory effect on 
Hydroxymethylglutaryl Coenzyme A (HMG-CoA) reductase. This subsequently led to the 
further development of other HMG-CoA reductase inhibitors, the statins. In 1987 
lovastatin became available for prescription as the first statin of its class. Statins have 
subsequently been documented to have beneficial effects on mortality and morbidity in 
patients with established CVD. A clear reduction of mortality with simvastatin in the 4S 
trial (127) and clear reduction in coronary events with very few adverse effects resolved 
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the cholesterol controversy in the 1990s. Thereafter, statins have been found to reduce 
the incidence of cardiovascular events in individuals without known CVD from the 
general population (128, 129). The Heart Protection Study (HPS) and the JUPITER trial 
subsequently demonstrated a clinical benefit in a broad population, including those with 
low cholesterol levels (130, 131). 
 
Types of statins 
Statins vary in their potency to inhibit HMG-CoA reductase and can be differentiated 
according to how they dissolve in lipids or water into lipophilic and hydrophilic, 
respectively. Due to these properties, the different types of statins differ with regard to 
their lipid-lowering effects, their side effect profiles, as well as to the way they are 
eliminated. Rosuvastatin is the most potent inhibitor of HMG-CoA reductase on the 
market, followed by atorvastatin and simvastatin. Hydrophilic statins, pravastatin and 
rosuvastatin, have less tissue absorption, except for the liver, and have fewer side effects 
due to lower dependence on the cytochrome p450 enzyme (132).  Lipophilic statins are 
considered more likely to enter vascular cells by passive diffusion than hydrophilic 
statins. Examples of statins from the lipophilic group are simvastatin, atorvastatin and 
fluvastatin. Clinical trials comparing lipophilic with hydrophilic statins have yielded 
varying results and potency and dosage seem to have greater impact on clinical 
outcomes. In the PROVE IT–TIMI 22 study intensive statin therapy (80 mg of 
atorvastatin) was superior to treatment with a moderate statin (40 mg of pravastatin) in 
terms of protection against death or major cardiovascular events in patients with a 
recent acute coronary syndrome (133). 
 
Pleiotropic effects of statins 
Statins have been proposed to exert important effects on the immune system that are 
independent of the effect on lipids, i.e. pleiotropic effects, which means that they are 
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producing more than one effect (134). The term “pleiotropic” is derived from the two 
ancient Greek words “pleio,” meaning many, and “trepein,” meaning influencing.             
Beside the cholesterol lowering effect, statins also inhibit the so-called isoprenoid 
synthesis, as illustrated in Figure 7, which results in antioxidant effects and the up-
regulation of endothelial nitric oxide synthase, an enzyme involved in vascular 
endothelial function.  
 
 
 
 
Figure 7: Cholesterol and isoprenoid synthesis influenced by statins (reprinted with 
permission from Davignon J et al, VHaRM 2005 (135)). 
 
Additionally, several inflammatory markers, such as CRP and nuclear factor-kB, have 
been shown to be reduced by statins, leading to the hypothesis that statins possess anti-
inflammatory properties (136-138). Other suggested mechanisms for pleiotropic effects 
of statins include immunomodulation, normalization of sympathetic outflow, plaque 
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stabilization, reduced activation of the blood coagulation cascade, and the inhibition of 
platelet aggregation (136). Anti-inflammatory actions seem to contribute to the 
beneficial cardiovascular effects, but controversy remains regarding the mode of action 
and impact of non-cardiovascular effects of statins. There are also clinical trials 
suggesting that statin benefits are independent of LDL-cholesterol reduction. As in the 
JUPITER trial, rosuvastatin was beneficial in the primary prevention of CVD in patients 
with elevated baseline inflammation (hsCRP >2 mg/L) but relatively low cholesterol 
levels (<130 mg/dl (3.4 mmol/L)), and other cardiovascular risks (131). In that trial, 
individuals with lower LDL-cholesterol and CRP after treatment benefitted particularly, 
which supports the importance of inflammatory components in the treatment of CVD 
and support the non-cholesterol-dependent effects of statins since the reduction of CRP 
by rosuvastatin was not related to LDL-cholesterol reduction. Another study measured 
the effect of rosuvastatin on coronary atherosclerosis in patients with ischemic heart 
disease and found that treatment with rosuvastatin significantly reduced intracoronary 
plaque volume and increased lumen volume without a significant correlation between 
LDL-cholesterol and plaque volume reduction (139). 
 
Statins and COPD  
In retrospective observational, case-control studies and population-based analyses, 
statin therapy has been associated with improved survival in patients with COPD (140, 
141), a reduction in COPD exacerbations as well as in number of and time to COPD-
related intubations and improved pulmonary function (142, 143). However, it remains 
unclear whether statins exert potential beneficial effects in COPD by primarily affecting 
vascular or respiratory function and whether a beneficial effect is mediated by 
attenuation of systemic inflammation or not. Experimental data suggest that statins may 
have beneficial effects on airway inflammation, matrix metalloproteinase activity, and 
mucin production (144-146). In rat models, simvastatin ameliorated the development of 
cigarette smoking–induced emphysema and pulmonary hypertension (147). 
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At the time when our project was initiated, two randomized placebo-controlled trials on 
statin treatment among patients with stable COPD had been published, as presented in 
Table 2. The first study (148) was double blind and included 125 patients with stable 
COPD. They reported a beneficial effect of pravastatin treatment on exercise time. The 
effect was more prominent among patients with decreasing levels of CRP during 
treatment. The second study (149) was open labelled, included 56 patients and failed to 
demonstrate any significant effect on circulating inflammatory biomarkers.  
A summary on publications of randomized controlled trials (RCTs) on the effect of 
statins in COPD patients is presented in table 2. With only limited data on statin effect in 
COPD populations from double-blind RCT’s and no data on the effect of rosuvastatin on 
endothelial function in stable COPD, we wanted to add knowledge about the effect of 
statin treatment on the vasculature, pulmonary function and systemic inflammation. 
 
Table 2: Publications of RCTs addressing statins and COPD until the year 2010. 
Year Author Population Study 
Type 
Statin Outcome Follow up 
2008 Lee (93) Stable COPD.  
n=125 
RCT 
Double 
blinded 
Pravastatin Exercise time, 
CRP 
6 months 
2010 Kaczmarek 
(94) 
Stable COPD, 
n=56 
RCT 
Open 
labelled 
Simvastatin CRP, IL6, MMP, 
TNFα, 
fibrinogen 
3 months 
 
CRP, C-reactive protein; COPD, chronic obstructive pulmonary disease; IL6, interleukin 
6; MMP, matrix metalloproteinase; TNFα, tumor necrosis factor alpha. 
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RATIONALE AND AIMS OF THE PRESENT STUDY 
Rationale 
The introduction demonstrates the importance of understanding the relationship 
between COPD and cardiovascular disease, including possible pathophysiological 
mechanisms, diagnostic methods, predictive factors, as well as treatment options.  
On initiation of this project, previous studies describing markers of myocardial injury 
were mainly of retrospective design, did not use the newest high sensitivity cTnT assay 
and had focused on patients with chronic obstructive pulmonary disease in the 
exacerbated state. Further, there were several observational studies describing a 
beneficial cholesterol-independent effect of statin treatment in COPD patients, but 
randomized controlled trials were sparse.  
With the new high sensitivity cTnT assay available, we wanted to evaluate subclinical 
myocardial injury and its prognostic value in patients with AECOPD in a prospective 
cohort study. However, with most COPD patients being in the stable state of the disease 
we also wanted to expand our investigations and describe the prevalence of subclinical 
myocardial injury in stable COPD patients compared with the general population.  
Finally, with the promising data from several previous retrospective studies, clearly 
suggesting a beneficial effect of statins in COPD, we wanted to shed light on a potentially 
beneficial treatment effect of statin therapy on vascular function, lung function and 
biomarkers in stable COPD patients in a randomized double-blind controlled clinical 
trial.  
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General aim 
The general aim was to assess the prevalence and prognostic value of subclinical 
myocardial injury measured by cardiac troponin T and to evaluate the effect of statin 
treatment on vascular function, pulmonary function and systemic inflammation in 
patients with COPD.  
 
Specific aims of the papers 
1)  To prospectively assess the prognostic value of cardiac troponin T measured 
with a high-sensitivity assay in patients hospitalized with an exacerbation of 
COPD (paper I). 
2) To assess the levels of cardiac troponin T measured with a high-sensitivity assay 
in COPD patients in the stable state of the disease compared to a sample from the 
general population (paper II). 
3)  To test the hypothesis that treatment with rosuvastatin for 3 months is 
associated with improved endothelial function assessed by peripheral arterial 
tonometry, improved pulmonary function assessed by spirometry and reduced 
systemic inflammation assessed by measurement of interleukin 6 and C-reactive 
protein in stable COPD patients (paper III). 
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MATERIALS AND METHODS 
“No one does anything right in life, until they realize that they are making a mistake”                    
(Albert Einstein) 
 
 Material 
Study design and subjects 
Paper I is based on the results of a prospective cohort study of 99 patients who were 
included from January 3rd 2005 through to November 30th 2006. All data were manually 
entered into a Microsoft Access 2000 database. Mortality status through December 31st 
2008 was retrieved from the hospital’s electronic records, which are annually updated 
with the National Population Registry. All patients in paper I were eligible for 
preliminary inclusion if admitted through the emergency department of the Akershus 
University Hospital with assumed AECOPD. The recruiting physicians had no knowledge 
of any laboratory results. The attending physicians and nurses in the emergency 
department were instructed to record clinical information on a one-page form and blood 
samples were drawn and subsequently stored in a bio bank. The completed form was 
collected by the recruiting physician and stored in a designated box at the emergency 
department.  An assigned physician collected the submitted forms the following morning 
and contacted the patients on the ward to retrieve written informed consent and 
medical history. Exclusion criteria were: age<50 years, metastatic cancer and Eastern 
Cooperative Oncology Group (ECOG) performance status ≥2, neuromuscular disease 
with respiratory failure, or anticipated non-cooperability.  
Paper II is based on the results of a prospective cohort study in which 101 patients were 
included from June 23rd 2009 through October 11th 2011. Patients were recruited from 
the outpatient department and were eligible if they had an established diagnosis of 
COPD stage I to IV after GOLD criteria and were within the age range between 40 and 80 
years. Patients received study information and consent form per mail and were 
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contacted 1 week later per telephone and asked if they were willing to participate in the 
trial. Patients were classified as stable if they did not have worsening of their respiratory 
symptoms beyond normal day-to-day variation or change in medication at least three 
weeks prior to inclusion. Exclusion criteria included diagnosed lung disease other than 
COPD, except asthma, prior history of cardiovascular disease, congestive heart failure, 
valvular heart disease, significant arrhythmias or conduction delays, uncontrolled 
arterial hypertension, body mass index >40 kg/m2 and significant neurological or 
haematological disorder. The subjects serving as references in paper II consisted of 120 
individuals, male or female, living in ten municipalities in the hospital’s catchment area. 
They were invited after random selection from the National Population Registry 
between 2006 and 2008. Data were manually registered into a Microsoft Excel database 
and exported into a SPSS - database. 
Paper III is based on a randomized, controlled, double-blind, clinical trial (Effect of 
ROsuvastatin Therapy on Peripheral VasoDilator Function, Inflammatory Markers and 
Pulmonary Function in Patients with StablE Chronic Obstructive Pulmonary Disease 
(RODEO)) in which 99 patients were included from March 22nd 2010 until July 10th 
2013. Eligible patients were recruited from the outpatient clinic of Akershus University 
Hospital and from the outpatient clinic from Haukeland University Hospital. Patients 
were eligible if they had a verified diagnosis of COPD stage I to IV after GOLD criteria and 
were between 40 and 80 years of age. Exclusion criteria included any other diagnosed 
lung disease except chronic asthmatic bronchitis and mild bronchiectasis, any history of 
or active coronary artery disease, cerebrovascular or peripheral vascular disease, 
history of or clinically significant congestive heart failure, valvular heart disease, 
clinically significant arrhythmias or conduction delays, uncontrolled arterial 
hypertension (defined as blood pressure above 180/110 mmHg with or without the use 
of antihypertensive medication), body mass index >40 kg/m2, history of diabetes 
mellitus or measured fasting glucose >11 mmol/L, history of hypercholesterolaemia or 
measured total cholesterol >8 mmol/L, known poliomyelitis, motor neuron disease, 
cranial or temporal arteritis, stroke or myopathy, neutropenia or aneamia (Hb <8 g/dL), 
history of chronic renal failure, serum creatinine >176 μmol/L (2.0 mg/dL) or creatine 
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kinase >3 times the upper limit of normal (ULN), acute or chronic liver disease (serum 
transaminases >3 times the ULN), pregnancy (self-reported and blood test prior to 
inclusion) or active abuse of drugs or alcohol or poor compliance anticipated.  
There was no run-in period in the trial and participants were randomly assigned to 
either rosuvastatin 10 mg or placebo once daily for 12 weeks and there was one control 
investigation after the treatment-period. Due to slow recruitment, patient inclusion was 
extended to the Haukeland University Hospital, Bergen, Norway, where 8 patients of the 
total of 99 patients were recruited from the pulmonary outpatient clinic and 
investigated after the same criteria. The complete trial was monitored by the 
department of Good Clinical Practice (GCP) from the Oslo University Hospital, Oslo and 
by Innovest AS, Bergen with a total of 6 and 3 monitoring visits, respectively. Data were 
recorded electronically and on a paper case report form (CRF). They were manually 
entered into a Microsoft Excel database and exported into a SPSS-database.  
 
Sample size determination 
Sample size calculation for paper I was based on a pilot study on 29 consecutively 
hospitalized patients with AECOPD by Brekke, Omland and Søyseth. They found, that 
seven patients (24%) had cTnT above normal levels (≥0.04), using a fourth generation 
assay. Six of these (86%) died during a 10 month follow-up, compared with two (9%) of 
the patients in the group with normal cTnT levels. Assuming a 50% increased mortality 
in the group with elevated hs-cTnT, α=0.05 and a prevalence of elevated hs-cTnT of 
25%, 104 patients were necessary to achieve 90% power to detect a significant 
association between hs-cTnT and mortality.  
Sample size calculation for the study population of paper II and III was based on the 
measurement of peripheral vasodilator function. Based on previous small, unpublished 
studies of healthy individuals at the Akershus University Hospital (night shift work and 
endothelial function, n= 12) and from the literature, the standard deviation for the 
difference between two repeated Endo-PatTM measurements used was 0.59 (150, 151).  
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We assumed initially that statin treatment is associated with a 30% increase in the 
reactive hyperemia index (RHI) in the statin group, and calculated that the study would 
have 80% power (α=0.05) with 61 patients per arm. Including an expected cross-over 
rate of 10% in both groups we initially planned to include 70 patients per arm. Due to 
additional information and literature on test-retest reliability during the study period  
(152) and reduced number of available patients the power calculations in the protocol 
were revised in 2013. According to the publication of McCrea and colleagues (152), 
considering an absolute change in the PAT hyperaemia ratio of 0.25 units 
(corresponding to a 10% increase in RHI from pre- to post-treatment, based on RHI 
measured in the population with stable COPD from our cross-sectional study), 72 
patients (36 per arm) were required to obtain a power (1- ß)  0.80 at an α of 0.05. Given 
an expected cross-over rate of 10%, the study was considered to be sufficiently powered 
with 50 patients per arm as by October 2013. There was no separate sample size 
calculation for the cross-sectional part of the study.  
 
Methods 
Endothelial function  
Endothelium-dependent vascular function was assessed by peripheral arterial 
tonometry (PAT) (EndoPATTM, Itamar Medical,Caesarea, Israel ). Digital pulse wave 
amplitude (PWA) was recorded with a finger probe of the PAT device prior to and 
during reactive hyperaemia, induced by occluding the arterial blood supply to the non-
dominant forearm for 5 minutes by a blood pressure cuff. The occlusion pressure was at 
least 60 mmHg above systolic blood pressure (minimally 200 mmHg, and maximally 
300 mmHg). Forearm occlusion has been shown to be less uncomfortable for the patient 
and to yield the same results as upper arm occlusion (153). An inflatable rubber balloon 
on the inside of the finger probe is filled with air after being placed on the finger and 
puts a counter pressure of 70 mmHg on the finger to avoid venous pooling of blood and 
veno-arteriolar reflexes. Each recording consisted of 7 minutes of baseline 
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measurement, 5 minutes of occlusion measurement, and 7 minutes post occlusion 
measurement (hyperemic period). The reactive hyperemia index (RHI), a measure of 
peripheral vasodilator function, was calculated using a computerized automated 
algorithm (software version 3.4.4). The RHI is the ratio of the average PWA during the 1-
minute period beginning after exactly 60 seconds of reactive hyperaemia compared with 
the average PWA during a 210 second pre-occlusion baseline period. Hamburg and 
colleagues described earlier that the relation between cardiovascular risk factors in the 
Framingham cohort and PAT hyperemic response was strongest in the 90- to 120-
second interval after fingertip flow was restored (154). To decrease the effect of 
confounding factors, the ratio is normalized to the concurrent pulse wave amplitude 
signal of the contra-lateral arm.  
 
 
Figure 8: EndoPATTM recordings of subjects with normal and abnormal reactive 
hyperemic response, reprinted with permission from Bonetti et al., JACC 2004 (64). 
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This method has been shown to correlate well with the vasodilator response of coronary 
vessels following infusion of the endothelium-dependent vasodilator acetylcholine (155) 
and to provide prognostic information concerning the future incidence of cardiovascular 
events in the general population (156, 157). 
The subjects were in supine position for a minimum of 20 minutes before 
measurements, in a quiet, temperature-controlled (21–24°C) room with dimmed lights. 
All measurements were performed in the morning and the subjects were asked to 
remain as calm and silent as possible during the entire measurement period. 
Cyclooxygenase inhibitors, cardio active drugs, alcohol, food, sweetened beverages, 
caffeine and smoking were prohibited the last 12 hours prior to the study. All 
measurements were performed according to the manufacturer’s instructions. An 
example of a result of EndoPatTM measurement is presented in Figure 8 with a normal 
response above and an abnormal response below. 
 
Blood samples  
cTnT: The hs-cTnT concentration in serum was measured with the Elecsys 2010 
Troponin T hs STAT assay (Roche Diagnostics, Mannheim, Germany). The 99th percentile 
for hs-cTnT in a healthy reference population was 14ng/L, 95% confidence interval 
12.7-24.9ng/L. The lowest concentration with a coefficient of variation (CV) less than or 
equal to 10% with the Elecsys Troponin T hs STAT assay was 13 ng/L. The Elecsys 2010 
Troponin T hs STAT assay has a detection limit (LoD) of 5.0 ng/L and a limit of blank 
LoB) of 3.0ng/L. LoB is the highest apparent analyte concentration expected to be found 
when replicates of a blank sample containing no analyte are tested. LoD is the lowest 
analyst concentration likely to be reliably distinguished from the LoB and at which 
detection is feasible. 
NT-proBNP: and IL6:  N-terminal pro B-type natriuretic peptide (NT-proBNP) and 
interleukin-6 (IL6) concentrations in serum/plasma were measured with the Cobas 
e602 (Roche Diagnostics, Mannheim, Germany). NT-proBNP has a LoD of 0.6 pmol/L 
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and IL6 has a LoD of 1.5 pg/ml. The analytical repeatability of the NT-proBNP method 
was 1.6% (level 14.6 pmol/L) and for the IL6 determinations the repeatability was 3.1% 
(level 12.1 pg/mL) (Roche Diagnostics, Mannheim, Germany). 
CRP: The CRP concentrations in serum were measured with a high sensitive method 
using the Cobas c 311/501 analyzer (Roche Diagnostics, Mannheim, Germany). hsCRP 
has a LoD of  0.15 mg/L (1.43 nmol/L, 0.015 mg/dL) and the analytical repeatability of 
the hsCRP method was 1.0% (level 4.34 mg/L). 
 
Spirometry 
Spirometry with reversibility testing with salbutamol was performed at the outpatient 
clinic as recommended by Miller (158). COPD patients were classified into four 
categories (A-D) in accordance with the combined COPD assessment of the revised 
GOLD strategy document, including associations between symptoms (MMRC scale), 
spirometric classifications and future risk of exacerbations (7). Since the questionnaire 
about dyspnea did not exactly reveal the number of exacerbations within the last year 
prior to inclusion (appendix), patients with GOLD I and II were contacted one more time 
about previous exacerbations, and hospital records were checked for hospitalizations in 
this period.  Some patients had a FEV1/FVC>70 with a previously secured COPD 
diagnosis. By evaluating the spirometric time volume curve we identified patients who 
did not exhale completely 6 seconds and are therefore expected to have a lower 
FEV1/FVC than recorded. Those patients were kept in the trial and the others were 
excluded.  
 
Six-Minute Walk Test 
The Six-Minute Walk Test (6MWT) was performed after the ATS Statement Guidelines 
(159). The tests were performed by the nurses at the pulmonary outpatient clinic in the 
  
45 
 
 
morning. Some of the patient performance was curtailed in addition to dyspnea due to 
local pain in the hip, feet or legs and documented accordingly. 
 
Dyspnea scale 
All subjects completed a questionnaire on respiratory symptoms according to the 
modified Medical Research Council (mMRC)  dyspnea scale) (160). The mMRC scale was 
used as an objective measure of stable-state breathlessness, which is associated with 
level of disability.  The questions concerning the mMRC scale were a part of a composite 
questionnaire on smoking status and history, other symptoms such as cough and 
wheezing and use of antibiotic therapy prior to inclusion. After inclusion, patients filled 
out the questionnaire by themselves, but they were checked for completeness by the 
investigating physician and completed in cooperation with the patient if necessary.   
 
Electrocardiogram  
An electrocardiogram (ECG) was recorded with CardioSoft PC Based 12 Lead 
Interpretive ECG System (Version V6.51) (GE Medical Systems, Milwaukee WI 53223 
U.S.A.). ECGs were evaluated by two independent physicians in paper III, and by one 
physician in paper II. ECGs were scored with regard to the following measures: rhythm, 
left ventricular hypertrophy (LVH, Sokolow-Lyon criteria), right ventricular 
hypertrophy (RVH), current ischemia (ST-segment depression), and prior MI 
(pathological Q wave, T-wave inversion or left bundle branch block (LBBB). ECGs were 
evaluated independently and blinded for all other data.  
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Chest radiographs 
Chest radiographs were acquired routinely in almost all patients admitted with 
worsening of dyspnea had chest radiographs taken on admission. After May 2005, these 
were electronically processed and stored, whereas the older radiographs were on 
conventional X-ray films. During 2010, two experienced physicians (one radiologist and 
one pulmonologist) analyzed the chest radiographs taken on admission. It was also 
noted whether the radiograph was taken in the erect or supine position and the 
investigators systematically determined the presence or absence of the following 
variables: cephalization of the lung veins (a composite of Kerley B-lines, enlarged vessels 
in the lung apex, peribronchial cuffing, perihilar haze, and interstitial or perihilar 
edema), pneumonic infiltrates, pleural effusion, and the heart/thorax ratio.  
 
Ethics 
The study protocol for paper I and the RODEO protocol for paper II and III were 
approved by the Regional Committee for Medical Ethics (S-09266c 2009/5732 
(RODEO)), and all participants received written and oral information before providing a 
written consent for participation. The privacy protection and establishment of database 
and bio bank were approved by the Norwegian Data Inspectorate and Norwegian Health 
Inspectorate, respectively. The interventional part of the RODEO study described in 
paper III was conducted in compliance with Good Clinical Practice (GCP) regulatory 
requirements and with approval from the Norwegian Medicines Agency and the 
independent ethics committee in accordance with the Declaration of Helsinki, with the 
informed, written consent of all participants. 
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Statistical analysis 
Univariate analysis 
All variables were investigated for distribution and outliers by plotting the data. This 
confirmed that the distributions of hs-cTnT, IL6 and hsCRP were skewed, with long right 
tails. hs-cTnT was categorized with cut-offs at 14ng/L and 39ng/L in paper I, and 
measurements of hs-TnT below the limit of blank (LoB) and between the limit of blank 
and the LoD [15] were replaced with LoB/2 and LoD/2, respectively in paper II. Baseline 
data are presented in the first table in all papers. Baseline characteristics of the study 
population were summarized within each randomization group in paper III. We used 
Chi-square and Fisher’s exact test on categorical variables, Student’s t-test on 
continuous variables, and univariate linear regression analyses to evaluate the 
relationship between two continuous variables. Performing these initial analyses to 
select variables for further analyses, a p-value <0.20 was considered the entry criterion.  
 
Survival analysis paper I 
In paper I the primary outcome variable was survival time. The final analysis included 
repeat admissions in extended survival regression models. When examining univariate 
associations between covariables and mortality, we calculated mortality rates (MR) and 
compared them using age-adjusted log-rank tests. All recorded admissions were used in 
this analysis. In the multivariable survival analysis all admissions were used in extended 
Cox regression analysis with time-dependent covariables.  
 
Regression analysis paper II 
We used least square univariate linear regression for continuous covariates categorized 
in quartiles with log-transformed hs-cTnT (ln[hs-cTnT]) as the dependent variable to 
detect linear trends. Additionally, Pearson’s correlation analyses were performed in 
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order to investigate associations between relevant continuous determinants for hs-
cTnT. For each category of the covariate hs-cTnT was expressed as the geometric mean 
because of its skewed distribution. The association between hs-cTnT and COPD was 
investigated using multiple ordinary least square regression adjusting for covariates 
that were associated with COPD as well as hs-cTnT with corresponding p-values less 
than 0.2. The initial full model was reduced by backward elimination if the p-value for 
association between ln[hs-cTnT] and the covariate was ≥0.05 and if removal of the 
covariate did not change the association between ln[hs-cTnT] and COPD > 20%.  
 
ANCOVA analysis paper III 
For rosuvastatin vs. placebo, the difference in change between the treatment groups 
from baseline to 12 weeks for primary and secondary end points and feasibility 
measures was estimated using analysis of covariance (ANCOVA) with the posttest as 
outcome and pretest as covariate (161). The primary analysis of efficacy endpoints used 
an Intention to Treat (ITT) population, which included a Complete Case (CC) analysis. 
Linear regression analysis was predefined to be adjusted for variables with a possible 
impact on the primary endpoint endothelial function. The primary analysis of efficacy 
endpoints also used a sensitivity analysis of the ITT population (all patients as 
randomized) with simple imputation techniques for missing values, using three 
imputation models with no change and a major positive (50%) and a major negative 
(50%) change each for the missing values. Another analysis of efficacy endpoints used a 
per-protocol (PP) population. The analysis of safety endpoints used a safety population. 
The per-protocol population excluded individuals who discontinued the study or who 
had low study compliance with more than 40 unused tablets at study termination (n=8). 
The safety population included all participants in the group, based on treatment actually 
received. Additionally, treatment effects in predefined subgroups with elevated 
circulating pro-inflammatory markers, defined as hsCRP above median value and IL6 
above median value were evaluated. Two posthoc sensitivity analyses were performed, 
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excluding patients with a) increased cardiovascular risk according to the Adult 
Treatment Panel III (ATP-III criteria) and b) a history of asthma.  
All statistical analyses were performed using SPSS Statistics software (IBM, Version 20) 
in paper II and III and STATA 10 (StataCorp LP, TX, USA) and SAS software (SAS 
Institute, Inc., Cary, North Carolina, USA, Version 9.1.3) in paper I. 
 
Literature search 
 
The main database source of literature in this work has been Medline.  Literature 
searches in PubMed and Ovid have used MeSH and self-selected search terms. Other 
database search has included Embase, Media center of World Health Organization, as 
well as search from reference lists from relevant publications. The literature has been 
limited to the English language.  
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SUMMARY OF PAPERS AND RESULTS 
Paper I 
Prevalence and prognostic value of cardiac Troponin T in COPD patients hospitalized for 
acute exacerbation of COPD. 
In this prospective study 99 patients with acute exacerbation of chronic obstructive 
pulmonary disease were followed until death or termination of the study. During a 
median follow-up time of 1.9 years, 57 patients (58%) died. 97 patients (98%) had 
measurable levels of hs-cTnT and 73 (74%) had hs-cTnT above the normal range (t 14.0 
ng/l). The crude mortality rates in patients having hs-cTnT <14.0, 14.0-39.9 and t 40 
ng/l were 4.6, 30.2 and 58.3 per 100 patient-years, respectively. Adjusting for relevant 
time dependent variables using an extended Cox regression analysis, the HRs (95% CI) 
for death were 4.5 (1.2 to 16) and 8.9 (2.4 to 32) among patients having hs-cTnT 14.0-
39.9 and >= 40 ng/l, respectively, compared with patients with hs-cTnT < 14.0 ng/l. The 
association between mortality and hs-cTnT was strongly modified by heart rate at 
admission (p<0.001) in the way that the association between hs-cTnT and mortality was 
stronger among patients with tachycardia. 
 
Paper II 
Prevalence of Troponin T in COPD patients in the stable state and its association with 
pulmonary function, inflammatory markers and comorbidity. 
In this cross-sectional study 101 stable COPD patients from the hospital's outpatient 
clinic and 120 individuals derived from a random general population sample were 
examined and compared with regard to levels of cardiac Troponin T and its association 
with pulmonary function, inflammatory markers as well as cardiovascular comorbidity. 
The crude geometric means of circulating hs-cTnT in the cases and the references were 
7.75 and 3.01 ng/l, respectively (p <0.001); that is, a relative ratio of 2.57 (95% CI 2.05 
to 3.23). After adjustment for relevant confounders, this ratio was moderately 
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attenuated to 1.65 (1.31-2.08). In the total study cohort, as well as among stable COPD 
patients, we found a significant positive association between hs-cTnT and IL6 
concentrations (p <0.001) and the presence of pathologic Q waves (p=0.023). Among 
stable COPD patients, one quartile increase in forced expiratory volume in one second 
(FEV1) was associated with a 39% decrease in hs-cTnT and patient category (Global 
Initiative of Obstructive Lung Disease classification 2011) was positively associated with 
hs-cTnT (p trend <0.001) after multivariate adjustment.  
 
 
Paper III 
Randomized, placebo-controlled, double-blind, parallel trial on the effect of short-term 
treatment of rosuvastatin on endothelial function, pulmonary function and inflammatory 
markers in patients with stable COPD. 
 
In this randomized, placebo-controlled, double blind, parallel trial 99 patients with 
stable COPD were assigned to receive rosuvastatin 10 mg (n=49) or matching placebo 
(n=50) once daily for 12 weeks. The primary outcome measure was change in 
endothelium-dependent vascular function measured with peripheral arterial tonometry 
and expressed as the reactive hyperaemia index (RHI). Secondary end points were 
change in pulmonary function, as assessed by FEV1 and FEV1/forced vital capacity 
(FVC), and change in the circulating inflammatory markers interleukin-6 (IL6) and high-
sensitivity C-reactive protein (hsCRP). In the overall study population, no significant 
between-group difference in change in endothelium-dependent vascular or pulmonary 
function was observed. Rosuvastatin therapy was associated with a reduction of hsCRP 
(–20% vs. 11%, p=0.017) and an attenuation of the rise in IL6 (8% vs. 30%, p=0.028) 
compared with placebo. In a prespecified subgroup analysis of patients with supra-
median circulating hsCRP concentrations (>1.7 mg/L), rosuvastatin was associated with 
improved endothelium-dependent vascular function (13% vs. 2%, p=0.026).  
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GENERAL DISCUSSION 
“If we knew what it was we were doing, it would not be called research, would it?”     
(Albert Einstein) 
 
Methodological considerations 
 
Internal validity 
Internal validity is the extent to which a conclusion based on a study is possible and is 
improved by the extent to which a study minimizes error (or 'bias'). Major threats to 
internal validity can be random error and systematic error.  
 
Random error  
 
Troponin measurement 
In paper I and II we measured TnT using a high-sensitive assay (hs-cTnT). The hs-cTnT 
analysis was introduced in clinical routine at the Akershus University Hospital 
laboratory in the year 2009. The laboratory staff at Akershus University Hospital 
performing the hs-cTnT analyses was trained, experienced and familiar with the 
equipment by the time of the analysis, and we have no reason to suspect errors related 
to the equipment or the use of the essays. hs-cTnT analyses in paper I were all 
performed in a single run and by  the same person from thawed samples. One third of 
the hs-cTnT analyses from paper II were analyzed continuously as a part of routine 
diagnostics at the Akershus University Hospital laboratory and two thirds were 
performed in a single run from thawed samples. One major challenge with the hs-cTnT 
assay is the level of analytic precision in the low concentration range. According to the 
manufacturer, the LoD is 5ng/L, the LoB is 3ng/L, the 99th percentile is 13ng/L, and the 
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concentration with a coefficient of variation of ≤10% is 14ng/L. The thawed samples 
had never been thawed before, were not transported long distances and all samples had 
been handled in the exact same way. We can however not completely rule out the 
possibility of random errors related to the handling, storage and thawing of samples in 
the study. According to the manufacturer, the specimens are stable for 24 hours at 2-8 
degrees Celsius and for 12 months at minus 20 degrees Celsius. The hs-cTnT assay has 
high tissue specificity with the assay antibodies binding to specific antigens that are 
exclusively found on cTnT proteins. There are no known reports of cross-reactions with 
other proteins. There is though still the possible bias of interference of hemolysis, 
heterophilic antibodies, human anti-animal antibodies, autoimmune antibodies, anti-cTn 
antibodies or fibrin clots (162-164).  
 
EndoPat measurement 
The digital PAT assessment is operator-independent due to control measurement of the 
contralateral arm and adjusting for systemic effects, it is easy to perform, and a strict 
written protocol was followed under all investigations. All measurements were 
performed at the same time of the day, in a fasting and smoke abstinent state, without 
intake of vasoactive medication and using standardized measurement procedures. We 
based the data on medication, food intake and smoking on oral information from the 
patient with smoking data supported by non-specific measurement of 
carboxyhemoglobin (CoHb). A discrepancy between recorded and real patient data is 
therefore still possible. All EndoPat™ measurements were performed after thorough 
training of the staff. The risk of a significant impact from random error related to the 
user is therefore low. The reliability and reproducibility of the digital PAT seem to be 
acceptable, although there is relatively few data on this subject with most studies 
published after the initiation of our study (152, 165-167). In comparison with FMD, the 
within-day variability for EndoPat™ measurements was higher (18% versus 10%, 
respectively, p<0.05), and the between day variability was similar (165). In larger 
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cohorts, the coefficient of variation for within-day variability (0.5-4 hours) was between 
15% and 22% with lower inter-day reproducibility (166, 167). 
 
Randomization and blinding 
Randomization is defined as the random allocation of a treatment between the 
treatment groups. Systemic differences can lead to the over- or underestimation of the 
difference between the treatment groups and can be avoided by this method. Random 
allocation means that each patient has a known chance, usually an equal chance of being 
given each treatment and that the treatment arm is unpredictable. Mostly, a table of 
random numbers or a random number generator on a computer is used for simple 
randomization. Other methods include block randomization which ensures closely 
similar numbers of patients in each group, and stratified randomization in order to keep 
the groups balanced for certain relevant patient characteristics (168, 169). We chose 
block randomization due to a relatively small sample size and slow recruitment pace in 
order to ensure a balanced number in the groups. Subjects were randomized 1:1 in a 
double-blind fashion to either rosuvastatin (active) or placebo using a computer-
generated code of random permuted blocks of four by a member of the data safety and 
monitoring board (DSMB). The sequence was stored in the pharmacy and concealed 
from investigators and participants. Treatment allocation was performed by an 
independent pharmacist. The active treatment and placebo had an identical capsule 
appearance. We did not stratify for certain patient characteristics, but predefined a 
multivariate model in the analysis to adjust for variables associated with the primary 
endpoint in case of an unpredicted misdistribution between the groups.  
 
Sample size  
The impact of random error, imprecision, can be minimized with large sample sizes.   
The size of the samples in this thesis were pre-defined by power calculations based on a 
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pilot study for the prospective study of paper I and on previous data on endothelial 
function for paper II and III as described previously. Sufficiently large samples are 
necessary to distinguish a small association from no association, so this is a relevant 
issue, in particular in cases where no statistically significant associations were found. 
The sample sizes were moderate in all papers and sample size could be an issue 
especially for paper III (risk of type II error) and is discussed in the relevant section. 
 
 Systematic error 
Selection bias 
The study population in paper I was approximately 14% of the sample population. Many 
AECOPD patients were admitted without being considered for inclusion in the study due 
to variable execution of tasks by the staff upon admission, which can represent a 
selection bias in this population. Inclusion rate might have varied due to the varying 
enthusiasm to inclusion of the staff, the general workload in the emergency department, 
and additional workload with a more severely ill patient or the failure to initiate 
practical procedures such as the gathering of relevant blood samples. Failure to include 
more severely ill patients might introduce systemic bias. However, comparing the data 
with other studies does not indicate that we have included particularly healthy patients. 
With a two-group design, selection bias might be of greater importance in paper II. 
Initially, a recruitment strategy of COPD patients in the stable state to paper II and III 
based on recruitment from general practitioners in the area was attempted, a method 
that proved ineffective. In the end, the study population consisted of patients recruited 
from the outpatient clinic at the Akershus University Hospital and Haukeland University 
Hospital. The fact that patients were recruited from the outpatient clinic may have 
introduced a possible selection bias as these patients may have more severe disease 
with a possible higher number of symptoms, comorbidities and exacerbations than the 
average COPD patient attending the general practitioner. The study population from 
paper II was approximately 35% of the sample population. The control sample from the 
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general population in paper II was collected prior to the inclusion of the COPD 
population. When comparing the population with the source population accessed from 
the Norwegian Central Statistics Office (table 07459, July 2011) we found that the 
sample population seems to be representative of the source population in the same 
period, that is, from 2006 to 2010. Patient selection to paper III is based on the same 
procedures as paper II, but with additional exclusion criteria due to the interventional 
design of the trial such as diabetes mellitus, previous or clear indication for statin use, 
and use of medications interacting with rosuvastatin. The study population from paper 
III was approximately 21% of the sample population and patients were mainly excluded 
because they did not wish to participate in a clinical trial, they were current statin users 
or because they had a history of cardiovascular disease or diabetes. The controlled, 
double blinded randomized design of paper III should prevent systematic differences 
between baseline characteristics of the groups. However, given the relatively moderate 
sample size, stratification during recruitment with regard e.g. to smoking status would 
have ensured a more balanced distribution between the groups. 
 
Confounding factors 
When evaluating an effect and an association between an exposure and an outcome one 
has to take confounding, effect modification and interaction into consideration. 
Confounding is a distortion in the estimated measure of association that occurs when 
the primary exposure of interest is mixed up with some other factor that is associated 
with the outcome. Effect modification is when the association between an exposure and 
the outcome depends on the level of a third variable, the effect modifier. Interaction is 
described as the heterogeneity of an observed effect (170) in terms of effect 
modification by other variables in more than one direction. In paper I we identified 
heart rate and redistribution of pulmonary flow from the bases to the apices of the lung 
due to pulmonary congestion (cephalization) as a possible confounder of the association 
between troponin T elevation and outcome. However, the mortality rates did not change 
noteworthy in adjusted analyses. No ECG measurements were included in the analyses 
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of paper I but were evaluated in a post-hoc analysis. In paper II important possible 
confounding factors were history of comorbidities such as inflammatory diseases, 
undiagnosed heart disease or heart failure and of course age, gender or reduced renal 
function. Adjusting for those factors in the multivariate model did though not alter the 
results. We did however not include other measurements of cardiovascular comorbidity 
in the analyses beside ECG measurements and the biomarker NT-proBNP. In the first 
two papers, sample sizes were too small to adjust for all possible confounders, which 
may have resulted in possible statistical instability and overfitting of the multivariate 
models. Through the randomization procedure we minimized the impact of confounding 
factors in the interventional study of paper III. Due to chance, a skewed distribution of 
factors is still possible. As this could possibly have influenced the primary endpoint 
result, vascular function, we predefined an analysis adjusting for age, active smoking and 
hypertension. Indeed, there was a significant difference in the number of patients with 
current smoking status in the placebo vs. statin group. However, adjusted analysis 
yielded similar results as the unadjusted analysis. We could of course also have stratified 
patients according to these important variables in order to ensure an equal distribution 
between the groups. Concerning age, we had a middle aged population and a quite small 
age range in the study population and a well-balanced gender distribution in all 
populations.  
 
Possible bias in the statistical analysis 
All data were plotted carefully and explored graphically in the initial exploratory 
analysis. Baseline analyses of distributions and univariable associations in paper I were 
performed on the 99 baseline admissions only in order to keep observations 
independent from each other. We used a non-parametric test (Kruskal-Wallis) for 
normally distributed variables due to simplicity reasons. Applying non-parametric tests 
to normally distributed data does not violate any assumptions, although p-values may be 
less conservative using a parametric test, like a t-test. In survival analysis the model of 
fit of a regular Cox model and an extended Cox model was tested by comparing the two 
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models’ log-likelihood criteria. The extended model based on 219 admissions in the 99 
patients had a better fit.  When using the extended model, the time from an observation 
until the end-point or censoring may be much shorter than the observation time for any 
individual. Therefore, it can be misleading to refer to the results as “long-term survival” 
or similar. In survival analysis of paper I most variables were dichotomized. This may 
have resulted in some information being lost as compared to using continuous variables, 
but at the same time permits assessment of effect modification in relatively 
comprehensible tables. In paper II we used quartiles of the continuous covariates, which 
could have caused some loss of information. However, by using quartiles we were able 
to better demonstrate a significant trend of hs-cTnT values for each covariate. In paper 
III we adhered strictly to the predefined analysis plan related to the primary and 
secondary endpoint and the pre-specified subgroup analysis in order to prevent 
multiple hypothesis testing and outcome-report bias. ANCOVA analysis was chosen for 
the analysis of the primary and secondary endpoint as it is a recommended and 
commonly used method in double-blind randomized clinical trial evaluation.  
 
External validity 
External validity is the extent to which the results of a study are applicable and 
generalizable to other situations and across populations. Recruiting COPD patients 
admitted for AECOPD might lead to a higher percentage of COPD patients of the frequent 
exacerbation phenotype. This cohort is therefore not representative for COPD patients 
in general, but was neither intended to be so. The aim was to assess troponin T status on 
admission for AECOPD and to gather subsequent mortality data. The study populations 
in paper II and III excluded patients with previously known cardiovascular disease. 
Cardiovascular disease is a common comorbidity in COPD patients and exclusion of 
these patients therefore influences the generalizability of the results in this trial. 
However, the introduction of such patients would have made the interpretation of 
results problematic. The population in paper II is not representative of a general COPD 
population, but can be generalized to a subgroup of COPD patients from a hospital 
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outpatient clinic in a presumably stable state and without previously known 
cardiovascular disease. The study population in paper III represents the same COPD 
patients from the outpatient clinic as in paper II, but with patients who are even more 
selected due to the strict exclusion criteria from the interventional part of the study. 
This population is therefore only generalizable to stable COPD outpatient clinic patients 
without clear indications for statin use and a generally lower cardiovascular risk profile.  
 
Summary of methodological considerations 
 
Taking the limitations in design and statistical analysis into consideration, the results 
from paper I and II seem suitable to describe prevalence and predictive value of 
troponin T as a marker of cardiac injury in COPD patients in the stable and the 
exacerbated state of the disease. Unrecognized subclinical heart disease in the source 
population could have been a source of type I error and supplemental information on 
cardiovascular comorbidity in the adjusted analysis would have been desirable. Paper III 
provides data of a well performed double-blind, randomized controlled clinical trial, but 
results should be viewed in relation to possible type II errors of weak associations 
between the intervention and the primary and secondary endpoints and need 
confirmation in larger clinical trials. The results of all papers are based on selected 
groups of COPD patients and are therefore not generalizable to a general COPD 
population.  
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Discussion of the results 
General findings  
The general findings of our studies are that patients with COPD show elevated levels of 
cardiac troponin T in the exacerbated as well as in the stable state of the disease and 
that cardiac troponin T predicts total mortality in AECOPD. In addition, statin treatment 
seems to primarily have a beneficial impact on the cardiovascular system in stable COPD 
patients with elevated biomarkers of systemic inflammation.  
 
Troponin T in exacerbated COPD patients     
Prior to the work with this thesis, retrospective studies have reported elevated troponin 
T levels in acute exacerbation of COPD measured with the conventional assay (121, 122, 
125). We confirmed these findings in our prospective study with a high sensitivity assay.  
We also observed that hs-TnT elevation was associated with increased risk of mortality 
in AECOPD patients.  
This is in agreement with the results from another prospective study from Chang and 
colleagues which was published only three months after the publication of paper I. They 
included 244 AECOPD patients without known CAD and showed that elevated levels of 
troponin T measured by the conventional assay strongly predicted 30-day mortality 
independently of other markers of severity and prognosis, but not long-term mortality 
(171). Marcun and colleagues prospectively investigated 127 AECOPD patients and did 
not find an association between troponin T and mortality but observed an association 
with rehospitalization in a 6-months follow-up period (172). However, causes for 
rehospitalization were not defined and with only 28% of the patients with elevated cTnT 
at admission and 19% at discharge the follow-up time might have been too short to give 
significant results with regards to mortality. They also used a fourth generation assay 
with a cut-off just above the detection limit and might therefore have missed low-grade 
troponin elevations. Kelly and colleagues recently found that troponin elevation 
together with severe acidosis and requirement for non-invasive ventilation were 
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associated with increased in-hospital mortality in patients attending the emergency 
department with an acute exacerbation of COPD (173).  
The prognostic value of hs-cTnT in our study from paper I was clearly modified by the 
heart rate of the patients in the way that hs-cTnT was a stronger predictor for all-cause 
mortality among patients with tachycardia. Although our study was not designed to look 
into causative mechanisms, tachycardia or arrhythmias might reflect cardiac strain in 
our trial resulting in elevated levels of cTnT. McAllister et al. (174) published a study in 
2012 describing that one in 12 COPD patients hospitalized for AECOPD met the criteria 
for myocardial infarction, including patients with common cardiovascular risk factors. 
Over half of the patients included had tachycardia. In an earlier study on exacerbated 
COPD patients from our hospital, raised troponin was found to be associated with lower 
hemoglobin and tachycardia (175). Tachycardia possibly represents underlying 
pathological mechanisms worsening the patient’s prognosis. Together with increased 
ventricular filling pressure as seen in heart failure, pulmonary hypertension or in 
pulmonary embolism, tachycardia might contribute to cTnT release from 
cardiomyocytes without myocardial cell death. Tachycardia can be triggered by 
AECOPD-related hypoxia, leading to pulmonary vasoconstriction with increased right 
ventricular afterload, potentially increasing right ventricular strain and dysfunction. 
Tachycardia, together with hypoxemia and increased afterload increases myocardial 
oxygen demand without meeting it, thereby inducing a type 2 myocardial infarction. In 
our study population we did however not find an association between hypoxemia and 
troponin elevation, but the use of supplementary oxygen on the way to the hospital 
might have influenced the results in the way that the level of oxygen was higher at the 
time of measurement in some patients. The association between slightly increased 
cardiac troponin values with tachycardia and other arrhythmias is generally well known 
in clinical practice. Troponin has for example been shown to be elevated among patients 
with atrial fibrillation and to improve risk prediction in this patient group (176). COPD 
has been shown to be a significant predictor of atrial fibrillation (AF) and atrial flutter 
(AFL) and non-sustained ventricular tachycardia (NSVT) (177). However, in our study 
only 7% had known atrial fibrillation. Pulmonary hypertension or embolism might be 
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additional reasons for cardiac strain, but we did not include imaging methods to 
investigate for these conditions in our study. Respiratory acidosis, reflecting 
decompensated respiratory failure can also lead to tachycardia and troponin release, but 
in our study, we did not observe such an association with the blood gas analyses being 
mainly in the normal range. Treatment with adrenergic agents is contributing to 
tachycardia in COPD patients, which can affect the myocardium with negative 
consequences, especially for patients with unrecognized heart disease. Patients with 
more advanced COPD with frequent exacerbations use higher amounts of adrenergic 
agents and are more likely to have underlying heart disease. Adrenergic medications 
should therefore have been included in the analysis. Post hoc analyses were therefore 
performed in 2013: the use of inhaled beta-adrenergic agents (short- or long-acting or a 
composite of the two) was associated neither with tachycardia nor with hs-TnT 
category.  
Other likely factors to explain the rise of troponin in AECOPD with subsequent increased 
risk include underlying coronary heart disease, the influence of ventricular hypertrophy, 
undetected ventricular dysfunction and systemic inflammation. Underlying coronary 
heart disease is likely to be underdiagnosed in this patient group due to similar 
symptoms (178). Campo and colleagues recently published a paper with the results from 
a prospective study including 694 AECOPD patients showing that cTnT actually failed to 
predict all-cause death. Only age, creatinine and NT-proBNP emerged as predictors for 
all-cause mortality in this population. However, cTnT was an independent predictor of 
cardiac death (CD), nonfatal AMI and the composite endpoint including CD and nonfatal 
AMI, with a stronger predictive value among patients without previously known IHD, 
suggesting subclinical IHD (179). Although a history of CHD was not associated with 
troponin in the population in paper I, we did not assess cardiac features of ischemic 
heart disease with electrocardiographic recordings or echocardiography, raising the 
possibility for an underestimation of the results. In post hoc analyses, ECGs from 
admission were therefore analyzed by two independent physicians. There was no 
association between higher hs-cTnT concentrations and electrocardiographic signs of 
prior MI, defined as pathological Q, loss of precordial R-wave progression or T-wave 
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inversion, (median values 29.8 vs 22.2 ng/L, p=0.15) or left bundle branch block (54.3 
vs. 24.9 ng/L, p=0.20).  
There is evidence that ventricular dysfunction is frequent during COPD exacerbations. 
Natriuretic peptides represent the gold standard for biomarkers in HF and have also 
been shown to be useful in excluding HF and to predict outcome (180). In our first study, 
we did not analyze biomarkers of myocardial strain such as BNP, but we used 
cephalization (upper lobe vascular redistribution) on the chest radiographs as a 
measure of left ventricular failure. NT-proBNP was later analyzed in the paper I cohort, 
and there was only a weak-to-moderate correlation between hs-cTnT and NT-proBNP 
(r= 0.34) (181). NT-proBNP was, however, elevated in the patients hospitalized with 
AECOPD and a significant predictor of long-term mortality in this population, 
independent of hs-cTnT. There was no association between NT-proBNP and ECG 
markers of right ventricular hypertrophy (RVH) or indices of prior MI, but an 
association was observed with peripheral edema. Taking the low sensitivity of the 
measurements used to detect heart failure in these patients into consideration, there 
might still be structural changes in the heart or diastolic dysfunction with impact on 
cTnT values and prognosis. Recently, Høiseth in our group compared a stable to a 
dynamic rise/fall pattern of hs-cTnT in AECOPD patients (182). Stable, moderately 
elevated hs-cTnT during AECOPD was associated with a poor long-term prognosis, 
independently of NT-proBNP concentration and a history of heart failure, suggesting 
possible subclinical structural changes in the heart, possible diastolic dysfunction and 
other additional possible factors contributing to cTnT elevation and its predictive value 
in AECOPD.  However, in this study the study population was quite small (a subgroup of 
the cohort of paper I, n=65), with only 12 individuals presenting stable and moderately 
elevated hs-cTnT.  
 The question of other possible factors contributing to the relationship between hs-cTnT 
and mortality in this patient group, such as chronic anemia and systemic inflammation 
has been raised earlier (183). AECOPD is associated with an increased inflammatory 
state, possibly contributing to increased cardiovascular risk due to endothelial 
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dysfunction, atherosclerosis, an increased pro-coagulant state and risk of plaque 
ruptures (184). Recently, Harrison and colleagues could show that thrombocytosis was 
associated with both 1-year mortality and in-hospital mortality in patients with AECOPD 
(185) suggesting an inflammatory role of platelets and a possible beneficial effect of 
antiplatelet therapy. Unfortunately, we did not perform comparable measurements in 
our study.  Recently, it has been demonstrated that COPD patients with frequent 
exacerbations have increased arterial stiffness as a measure of atherosclerosis. Arterial 
stiffness was also was related to inflammation (186). Kim and colleagues showed that 
untreated COPD patients had a higher level of CRP and carotid intima thickness than 
subjects without COPD (187). Seifarth and colleagues recently demonstrated that 
troponin T and high sensitivity CRP were related to plaque progression measured by CT 
coronary angiography, although not in a COPD population (188). However, in our first 
study we found no strong association between CRP levels or leucocyte count and hs-
cTnT, neither was the leukocyte count identified as an effect modifier in this population, 
which might be due to the limited number of biomarkers or patient number in our study.  
Finally, a recent hypothesis-generating study describes an interesting new aspect of a 
possible reason for myocardial damage and subsequent troponin release. Brown and 
colleagues describe the formation of cardiac microlesions and elevated troponin in 
relation with invasive infections with streptococcus pneumonia in mice (189). COPD and 
AECOPD is strongly associated with bacterial and viral infections (190). The pulmonary 
microbiome in COPD patients and infections in AECOPD are likely to play an important 
role in the inflammatory state of the disease and the development of structural changes 
in the lung and vasculature (191) as well as the myocardium, thereby influencing 
comorbidities and prognosis of these patients. There has been increasing interest in this 
field within the last years and further investigations are needed to shed light on the 
influence of the lung microbiome on cardiovascular comorbidity in COPD patients.  
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Troponin T in stable COPD patients  
 
With paper II we wanted to focus on stable COPD patients and compare troponin levels 
among patients in the stable state with a reference sample from the general population 
without COPD. We could demonstrate that troponin T also is elevated in patients with 
COPD in the stable phase of the disease compared to the general population.  
This is important because we believe that COPD patients hospitalized with an AECOPD 
present with aggravated disease related symptoms and comorbidities as a possible 
trigger for troponin release. Just before the publication of paper II, Søyseth et al. from 
our study group found that cTnT is elevated in another population with stable COPD 
patients and that the values differed significantly from patients hospitalized with 
AECOPD (192). This suggested that troponin elevation also is related to the exacerbation 
itself. This publication includes a slightly bigger sample (n=124) of patients in the stable 
state of COPD than paper II (n=101), but with similar inclusion criteria, methods and 
baseline values. Patel and colleagues (186) showed that troponin T levels increase 
during moderate COPD exacerbations compared to the stable state, that they do not 
recover for several weeks and that they relate to increased sputum purulence and 
exacerbation length. Patel and colleagues studied a population of 98 stable COPD 
patients, including some with ischemic heart disease (IHD). Our stable COPD patients 
had a higher prevalence of troponin T above the upper reference limit (URL) at 14ng/L 
with 29% compared to 17% and 16.4% in the other populations. Hattori and colleagues 
describe a prevalence of 9% with hs-cTnT above the URL, but they included patients 
with a life-long smoking history and COPD symptoms, of these were 63% diagnosed 
with COPD the other classified as being at risk of the disease, which is an interesting 
approach as COPD is likely to be underdiagnosed (193).  
The cross-sectional design of the study of paper II does not allow us any causative 
conclusions of the results, but it is hypothesis-generating about possible 
pathophysiological mechanisms underlying hs-cTnT elevation in the stable state of the 
disease. Troponin release could be partially mediated by an inflammatory process, e.g. 
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by increasing the permeability of the cell wall of the cardiomyocyte or by inducing 
cardiomyocyte apoptosis. In paper II, elevated IL6 was a significant predictor of cardiac 
troponin T in stable COPD patients. Troponin release has previously been shown to be 
elevated and related to inflammatory markers in marathon runners (194). Inflammatory 
markers such as leukocytes, CRP and IL6 have been shown to be elevated in COPD 
patients compared to smokers with normal lung function and nonsmokers in the 
ECLIPSE study (27). COPD patients with signs of a persistently increased systemic 
inflammation had a higher rate of exacerbations and worse survival. The result of 
troponin measurement and association with inflammatory markers in the same 
population is eagerly awaited. Søyseth et al described an association between leucocyte 
count and troponin T levels, an association that was apparently not mediated by the 
levels of IL6 or CRP. Hattori and colleagues described CRP as an independent predictor 
of hs-cTnT elevation in stable COPD. We identified an association between IL6 and 
troponin T levels in paper II. However, in contrast to Søyseth et al we found no 
association between hs-cTnT and neutrophil count. By only evaluating neutrophils as 
one subtype of leukocytes, we might have missed valuable information from other 
inflammatory cell types and components. In addition, the discrepancy of the results 
might also reflect the complexity of immunological action in COPD and maybe other 
markers of pulmonary or systemic inflammation might be more useful to describe the 
inflammatory state in COPD.  
Unrecognized ischemic heart disease could be another reason for cTnT elevation in our 
population. In paper II we excluded patients with previously known cardiovascular 
disease. We could identify four patients with a pathological Q-wave on the ECG and 
included this variable in the multivariate analysis of the paper. We can, however, not  
rule out the possibility of subclinical and undiagnosed ischemic heart disease in these 
patients without having performed invasive cardiovascular investigations such as 
coronary angiography. Patel and colleagues described a population with stable COPD 
with 20% ischemic heart disease (IHD) comprising stable angina, previous MI, and 
previous coronary artery intervention, such as bypass grafting, angioplasty and stenting 
(186). They confirmed our observation that myocardial injury measured by hs-cTnT is 
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common among stable COPD patients and extended our findings by demonstrating that 
hs-cTnT is commonly increased among patients with comorbid IHD. They also reported 
that arterial stiffness, another marker of cardiovascular risk, was related to serum 
troponin T (rho=0.350; p=0.001) but not to NT-proBNP(r= 0.161; p=0.146), which was 
within the normal range. In our population we also measured PAT as a marker of 
endothelial dysfunction and cardiovascular risk. We found no association between the 
reactive hyperemia index (RHI) measured by PAT and hs-cTnT (rho=0.158, p=0.114).  
Hattori and colleagues excluded all patients with a history and ECG signs of 
cardiovascular disease from their study. They reported in their paper on patients with 
early stage/stable COPD that, in addition to CRP, hs-cTnT values were independently 
affected by age and right ventricular systolic pressure (RVSP) assessed by 
echocardiography (193). Increased right ventricular pressure in stable COPD patients 
might represent pulmonary vascular remodeling, which has been shown in mild COPD 
and even in smokers with normal lung function (195). RVSP assessed with 
echocardiography, however, cannot define pulmonary arterial hypertension (PAH) 
alone, and the most direct and exact way of measuring pulmonary artery pressure is by 
right heart catheterization (196). Hilde and colleagues demonstrated nicely with right 
heart catheterization that stable COPD patients without previously known pulmonary 
hypertension have signs of subclinical reduced right ventricular function (197). To our 
knowledge there are so far no published studies directly relating pulmonary arterial 
pressure values to high-sensitivity cardiac troponin levels in patients with stable or 
exacerbated COPD. Therefore it is not quite clear to what degree pulmonary 
hypertension contributes to troponin elevation in stable COPD. 
Heart failure has been shown to be underdiagnosed among COPD patients, and about 
20% of COPD patients seem to have unrecognized heart failure (198, 199). The presence 
of heart failure signifies ominous prognosis in this patient group (200). It has been 
previously shown that BNP levels are increased during AECOPD and fall during recovery 
(201). Patel and colleagues demonstrated  that stable COPD patients with previously 
known ischemic heart disease (IHD) as assessed by the Charlson Comorbidity index, 
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have higher levels of NT-proBNP than stable COPD patients without IHD, but NT-proBNP 
levels and IHD were not predictive of the frequency of exacerbations but of exacerbation 
severity (202). In our population of stable COPD patients we found only modestly 
elevated levels of NT-proBNP, suggesting that congestive heart failure was not present. 
We evaluated the electrocardiographic measurements with the Sokolow-Lyon 
electrocardiographic voltage criteria, recognizing that these criteria have a low 
sensitivity for the detection of anatomic left ventricular hypertrophy and have 
previously been shown to vary according to the underlying heart disease (203).  
 
Most of the previously described studies on cTnT and cTnT have shown an inverse 
association between pulmonary function and troponin measurement among stable 
COPD patients (except for the study of Patel and colleagues where this association was 
not presented). In paper II we also described an inverse association between the new 
GOLD classification adding exacerbation risk and symptoms and hs-cTnT. We did not 
though observe a significant difference in the magnitude of thecorrelation coefficients 
between the old and the new GOLD classification and hs-cTnT (rho=0.48, p=0.001 
versus rho=0.47, p=0.001, respectively) in our population. This may be due to the fact 
that the new classification not sufficiently captures subclinical cardiovascular 
comorbidity and inflammation. COPD severity has been shown to be independently 
associated with the occurrence of atrial fibrillation and non-sustained ventricular 
tachycardia (177), both arrhythmias that can cause troponin release within this 
particular patient group. Patients with documented atrial fibrillation or other 
arrhythmias during the ECG recording were not included in the analyses of paper II, and 
there is thus no reason to suspect arrhythmic activity at the time of investigation as a 
reason for troponin elevation. However, since our patients did not perform a long-term 
Holter registration there is still the possibility of undetected arrhythmias that may have 
caused troponin release prior to investigations. Heart rate had a fairly narrow range in 
the stable COPD population and was not associated with troponin T in the population of 
paper II. 
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To the best of my knowledge there are at the time of writing this thesis no further 
publications investigating prevalence, determinants or the prognostic value of troponins 
in COPD patients in the stable state, and paper II provides valuable information 
comparing stable COPD patients with a presumably healthy reference population in 
terms of cardiac troponin values. Subclinical heart failure, myocardial strain, 
arrhythmias and systemic inflammation may represent direct and indirect stimuli for 
cardiac troponin release in the stable state of the disease, which might aggravate during 
a COPD exacerbation. Longitudinal and interventional studies are needed to document a 
causal relationship between these factors and hs-cTnT elevation in stable COPD as well 
as to investigate the prognostic value of cTnT measurement in this particular 
population. 
 
 
Statin treatment in COPD patients 
Observational studies have described a beneficial effect of statin treatment in COPD. 
This was recently confirmed in another observational study by Fruchter and colleagues, 
emphasizing the lipid-independent effect of statins in patients with COPD (204). With 
our interventional study we provided evidence that short-term treatment with 
rosuvastatin has a beneficial effect by improving vascular function in a subgroup of 
stable COPD patients without indication for statin therapy, but with elevated baseline 
CRP measured by a high sensitive assay.  
We did not find an effect of rosuvastatin treatment on our primary endpoint, endothelial 
function as assessed by EndoPAT, in the overall population. John and colleagues recently 
showed in a double-blind, placebo controlled randomized trial that statin treatment in 
stable COPD had no effect on pulse wave velocity as a measure of arterial stiffness and 
cardiovascular risk in the total population, which might be due to short treatment 
duration, low dosage of simvastatin or insufficient sample size using a short-term 
treatment of 6 weeks with simvastatin 20mg in 70 patients (205).  In paper III, sample 
size might also be an issue, but we considered the sample size to be sufficient for reliable 
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assessment of our continuous variable primary endpoint. However, the  dosage of the 
study medication and the duration of the the treatment period may potentially have 
contributed to the lack of significant results. In addition, most patients in our population 
did not demonstrate endothelial dysfunction at baseline, which could have reduced the 
likelihood of observing an improvement in the primary outcome variable, although a 
cutoff for a definition of endothelial dysfunction with EndoPat measurement has to be 
seen as arbitrary. In a prespecified subgroup analysis, John and colleagues  found that 
treatment with simvastatin reduced aortic pulse wave velocity (PWV) in those with a 
high baseline aortic PWV. They suggest a beneficial statin effect among stable COPD 
patients in terms of reduced cardiovascular risk in those not primarily targeted for 
primary prevention, which corresponds to our own results from paper III. The fact that 
we could identify a subgroup of patients with evidence of systemic baseline 
inflammation fits well with the established knowledge describing certain COPD 
phenotypes with elevated inflammatory markers and worse prognosis (206). However, 
there was no significant correlation between the lowering in CRP and the improvement 
in endothelial function. Neither was there a significant association between baseline 
CRP-levels and enothelial function in our study. These observations are in accordance 
with previous large epidemiological studies that found no clear association between hs-
CRP and RHI (156, 207). This suggests that although markers of systemic inflammation 
identify a subgroup of stable COPD patients that seem to benefit from statin therapy, 
these markers are not necessarily suitable as tools for monitoring the effect on 
endothelial function. It is also still unclear to what extend therapeutic improvement in 
endothelial function translates into lower CV morbidity and mortality in this patient 
group. Endothelial function is not considered a primary therapeutic target in the 
prevention of atherosclerotic disease (208). However, Modena and colleagues 
demonstrate that improvement in endothelial function measured by FMD in 
hypertensive post-menopausal women was associated with an improvement in 
cardiovascular prognosis (209). Kitta and colleagues also assessed endothelial function 
by FMD and showed that persistent impairment of endothelial dysfunction despite 
optimized medical therapy was a strong independent predictor of adverse CV events 
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among patients with coronary artery disease (210). These results can however not be 
extrapolated to a COPD population. In contrast to FMD , there is no clear evidence on the 
impact of therapeutic changes in RHI over time. Further studies should investigate if RHI 
might serve as a stable surrogate endpoint or possibly a risk factor for CVD in COPD 
patients as well as in other populations  (211, 212).  
In the total study population we observed an anti-inflammatory effect of statin therapy 
with a significant difference in change in hs-CRP and IL6 between the treatment groups. 
The effect on IL6 seems to be influenced by a rise of IL6 in the placebo group. This rise 
might represent progression of inflammation and disease in the placebo group, 
however, AECOPD during follow-up and IL6 was not significantly correlated (r=0.023, 
p=0.825). There was a significantly higher number of current smokers in the placebo 
group in paper III, which could have influenced the effect on inflammatory markers. 
However, we could not find a correlation between current smoking status and IL6 and 
CRP values in our population (r=-0.131, p=0.198 and r=0.037, p=0.713, respectively) 
and patients had abstained from smoking at least 12 hours prior to investigation. Most 
patients did not change their smoking status under the treatment period. Three patients 
(two in the placebo and one in the rosuvastatin group) mentioned that they had quitted 
smoking 1-2 weeks before follow-up, but this time period is considered too short as to 
declare them as non-smokers. Excluding these patients from the analysis did not alter 
the results. Therefore, we suspect no major impact of current smoking status in this 
context. Previous interventional studies have found conflicting results regarding an anti-
inflammatory effect of statin treatment in patients with COPD. Lee and colleagues 
described a significant effect of a six months treatment with Pravastatin 40mg in stable 
COPD (n=125) on CRP and IL6 (148). Kaczmarek and colleagues did not find a 
significant effect of a three months treatment with simvastatin 40 mg in stable COPD on 
five different inflammatory markers including CRP and IL6 (149), which might be due to 
small sample size (n=56) and short treatment period. John and colleagues did neither 
find an effect of treatment with simvastatin 20mg on inflammatory markers including 
CRP after a period of six weeks (205). Again, treatment period and study size might have 
been too small to provide significant results. Mroz and colleagues described the results 
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from a randomized, controlled, double-group pilot-study of 12-week treatment with 
40mg atorvastatin. They observed a significant decrease in neutrophils and eosinophils 
in sputum and a significant decrease in CRP in the blood samples from the treatment 
group compared to placebo. In lung biopsies, inflammatory cell numbers (CD45+ cells) 
decreased significantly in the placebo group. They performed transcriptome profiling in 
lung biopsies and also described a downregulation of immunological response genes in 
the atorvastatin group. However, the study was not blinded and the included number 
was small, with 5 patients in the placebo and 12 patients in the treatment group (213). 
Further randomized clinical studies with larger sample sizes are needed to confirm an 
anti-inflammatory effect of statins in stable COPD patients and the results from a large 
multi-center trial with simvastatin in regard to the anti-inflammatory effect are awaited 
as further described below (214).  
In our study, treatment with rosuvastatin did not improve pulmonary function. Potential 
explanations for the lack of effect on pulmonary function include the short treatment 
period of 12 weeks, the relatively low dose of rosuvastatin with 10 mg and the lack of 
increased inflammatory activation at baseline in a substantial proportion of patients. As 
mentioned above, the recently published large multi-center trial (STATCOPE) also 
reported no effect of long-term treatment with simvastatin on pulmonary function. The 
primary outcome in the STATCOPE trial was the COPD exacerbation rate and no effect of 
simvastatin was observed. However, STATCOPE and our study from paper III included a 
high percentage (>70%) of patients using inhaled corticosteroids, which might have 
affected and attenuated an additional effect of statin treatment in these groups due to 
the anti-inflammatory effects of the steroids. Additionally, the STATCOPE study did not 
limit inclusion to patients with elevated baseline inflammation and it remains to be seen 
if such a subgroup has a greater treatment effect in terms of increased pulmonary 
function or less exacerbations in this and other COPD populations.  
In a recently published observational study with 5794 unselected individuals from the 
general population statin use was associated with less COPD exacerbations but not  in 
patients without cardiovascular comorbidity, which suggests that statins only have a 
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beneficial effect  in COPD patients with coexisting cardiovascular disease (215). It 
remains unresolved what preventive effects there might be. A small triple-blinded, 
randomized clinical trial with atorvastatin for 6 months in COPD patients with 
secondary pulmonary hypertension reported no significant decrease in systolic 
pulmonary arterial hypertension and no significant improvement in six-minute walking 
distance (6MWD) (216). This is in accordance with our results, as we did not find an 
effect of rosuvastatin treatment in 6MWD. 
To be able to distinguish between a possible pulmonary or only cardiovascular benefit of 
statin treatment in COPD patients, large scale interventional studies with long-term 
follow-up over several years and hard cardiovascular outcomes are needed, including 
COPD patients with well characterized symptoms, risk profiles and subclinical 
cardiovascular comorbidity. 
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CONCLUSIONS AND PERSPECTIVES 
“If you can't explain it to a six year old, you don't understand it yourself”                        
(Albert Einstein) 
 
Conclusions 
In our studies we have assessed the prevalence and prognostic value of cardiovascular 
markers in stable and exacerbated COPD, respectively, and the effect of statin treatment 
on pulmonary and cardiovascular function as well as systemic inflammation in patients 
with COPD.  We have shown that cardiac troponin T, a marker of cardiomyocyte injury, 
is associated with outcome in patients hospitalized for COPD exacerbation. We have also 
shown that hs-cTnT is elevated among patients with COPD in the stable state compared 
to presumably healthy persons from the general population. Statin treatment in stable 
COPD patients does not seem to improve pulmonary function, but attenuates 
biomarkers of inflammation and improves endothelial function in a subgroup of patients 
with evidence of increased systemic inflammation at baseline. Cardiovascular 
comorbidity might be underdiagnosed in COPD patients, and statin treatment seems to 
have impact mainly on cardiovascular function in this patient group.  
 
Clinical implications 
Many COPD patients may have undiagnosed cardiovascular disease and more 
investigations are necessary to identify these patients in order to give them adequate 
treatment.  It remains a question though, which diagnostic measures should be used 
how and when in order to define the optimal treatment. Treatment should include a 
personalized medicine strategy, which should take the patients baseline inflammatory 
state into consideration and carefully assess possible underlying cardiovascular disease. 
Patients with a low risk profile but elevated systemic inflammation may still profit from 
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treatment even though there is no published evidence showing a clear beneficial effect 
of statin therapy in COPD patients with low cardiovascular risk beyond that of 
recommended primary prevention.  
 
Suggestions for future research 
Future trials in COPD patients should investigate COPD subgroups and phenotypes and 
focus on detailed mapping of COPD features such as genetics, symptoms, pulmonary 
infections and lung microbiome, medications and comorbidities with validated and 
specific methods. In order to do so it might be useful to use contemporary imaging 
techniques in trial populations such as echocardiography or MRI for cardiac evaluation 
and for example CT thorax for the evaluation of emphysema or bronchiectasis and 
coronary artery calcification. Sputum investigation and bronchoscopy provide valuable 
insight in intra-pulmonary state and features and should be considered further in future 
trials.  The predictive value of troponins in stable COPD patients should be assessed with 
a clear definition of the stable state of disease. Randomized clinical trials should 
investigate the effect of statins against the effect of corticosteroids among COPD 
patients, especially in subgroups with evidence of baseline inflammation. Study 
populations should include patients at an early and stable stage of COPD and with low 
cardiovascular risk, as assessed by different risk calculators.  Future studies should 
include long-term follow-up of cardiac and inflammatory biomarkers and use hard 
cardiovascular endpoints.  
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